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ANALYSIS OF SOL-GEL ENCAPSULATED AGGREGATE-PRONE PEPTIDES BY 
CIRCULAR DICHROISM 
 
by Nathan Birtwhistle 
 Protein aggregation has been linked to many debilitating neurological diseases.  In 
each case, a specific protein is thought to have a region of intrinsically disordered 
structure that seeds the aggregation.  Highly cooperative in nature, protein aggregation is 
difficult to investigate.  The current study aims to characterize two aggregation-prone 
peptides involved in Huntington’s disease, polyglutamine (polyQ, D2Q15K2), and 
Alzheimer’s disease, amyloid-beta (Aβ).  A protocol was developed to encapsulate the 
peptides by the sol-gel technique.  Generated from a liquid state, the silica matrix is 
presumed to isolate the soluble peptide, preventing aggregation.  In addition, the porosity 
of the glass allows the solvent conditions to be altered.  The peptides were characterized 
by circular dichroism spectroscopy (CD).  In solution, both peptides were most 
aggregation-prone when they contained the least amount of secondary structure.  
Encapsulated polyQ showed unique pH-dependent spectra not seen in solution.  Aβ was 
able to take on both a random coil and an apparent beta structure in 5% 
hexafluoroisopropanol (HFIP), depending on the prior solvent, indicating two semi-stable 
states of similar energy.  The results for both peptides show that (1) the encapsulated 
peptides can adopt a significant amount of helical secondary structure, (2) the secondary 
structure can be altered by varying the solution, temperature, and pH, and (3) most 
changes in structure appear to be reversible. These results are consistent with the absence 
of aggregation in the encapsulated samples.
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 In 1892, one of the first known reports of the presence of protein aggregates, or 
plaques, in the brains of deceased patients was documented by Georges Marinesco and 
Paul Blocq [1].  At the time they did not know that these plaques were made up of 
aggregated proteins and simply reported them as “senile plaques.”  In 1907, Alois 
Alzheimer published the first paper on the correlation between these plaques and 
dementia, linking protein aggregation to neurological atrophy [2].  The presence of 
protein aggregates has been linked to many other neurodegenerative diseases, but until 
recently the nature of these diseases still remained a mystery.  When Stanley Prusiner 
published his manuscript on prion disease in 1982, for which he won the Nobel Prize in 
1997, he opened the door to the nature of protein aggregation diseases [3]. 
 The nature of proteins, or polypeptides, is to fold into a structure with a functional 
purpose.  A peptide, a general term that will also be used to refer to proteins in this paper, 
is manufactured as a linear molecule made up of amino acids that may have one of two 
properties determined by its side chain: hydrophobic (nonpolar) or hydrophilic 
(polar/uncharged, acidic, or basic) [4].  It is the consecutive makeup of the peptide that 
determines its structure and function and is known as its primary structure.  Because of 
this structure, there are two classes of factors affecting the structural/functional content of 
a peptide, intrinsic and extrinsic.  Intrinsic factors include those derived from its primary 
structure such as genetic mutations, hydrophobicity, and electrostatics.  Extrinsic factors 
come from the surrounding environment and how it interacts with the peptide, such as 




influence on the peptide’s structure and function, and they provide the driving force for 
aggregation [5]. 
 A peptide’s natural tendency to aggregate comes from its intrinsic factors, i.e., 
from what amino acids it is made and how they are organized along the peptide’s 
backbone.  Generally, the more solvent-exposed hydrophobic amino acids a peptide 
contains, the more likely it is to aggregate; more specifically, the more ordered 
hydrophobic surface content and its concentration, the more aggregate-prone the peptide 
becomes [6-8].  As a consequence, proteins that form hydrophobic beta structures are 
more likely to aggregate, and those that remain soluble and/or form hydrophilic alpha 
helices are less likely [9, 10].  This tendency to aggregate may be due to the fact that beta 
structures are highly ordered sheet-like structures, making them complementary surfaces 
to each other.  Soto, et al. (1995, 1996), showed by inducing point mutations that proteins 
were more disposed to aggregate when helical content was reduced or beta content was 
increased and vice versa [11, 12].  Typically a peptide buries its hydrophobic content 
within its interior, shielding it from interacting with the aqueous (hydrophilic) solvent.  If 
a peptide is built such that it is unstable or natively disordered, then slight variations in 
solvent quality (temperature, hydrophobicity, etc.) may cause it to transition through 
different secondary structures and therefore become prone to aggregation. 
There are three ways by which solvent quality, or other external factors, may 
influence aggregation rates; they may favor intermediate formation, destabilize the native 
folded state, or stabilize the unfolded state [13].  Specific factors include temperature, 




fluctuations in temperature may destabilize the peptides, increasing intermediate 
concentration and diffusions rates.  This change increases the concentration of the 
aggregate-prone hydrophobic conformation and its likeliness to interact with another 
molecule, leading to aggregation.  Second, changes in pH affect the relative type and 
distribution of charges on the peptides’ surfaces.  Since the structures peptides can take 
on are directly linked to the way they interact with the solvent, these changes in pH will 
influence the peptide’s stability and structure.  Decreasing the number of 
charged/hydrophilic residues, those usually found on the surface, can destabilize the 
peptide and cause it to unfold, exposing the hydrophobic interior [14].  Third, since a 
small sub-population of peptides will be in the intermediate and unfolded states even at 
equilibrium, if a peptide’s concentration is increased, then effectively the concentration 
of the intermediates will also be increased, again enhancing aggregation [5].  At this point 
it should be noted that a theme is developing; there are two prerequisites to aggregation:  
a destabilized peptide and exposure of ordered hydrophobic content.  All other extrinsic 
factors causing protein aggregation meet these prerequisites and will be discussed more 
extensively below.  In essence, if a protein’s structure is changed, then so is its function; 
in this case the function is toxic in nature. 
Structure and function are synonymous in the world of peptides.  Slight energy 
variations in a peptide’s environment can potentially cause it to loose its native 
(functional) structure and gain non-native (toxic) function.  This work is a study of two 
peptides known to have a strong tendency to aggregate, and they are believed to be 




and unfolded sates.  The purpose of this work is to isolate these peptides within a sol-gel 
matrix that prevents aggregation, to induce the aggregate-prone intermediate transition 
state, and to characterize the resulting structure to study an early step in protein/peptide 
aggregation. 
 
1.1. Protein Aggregation and Neurodegenerative Diseases 
As the average human life span increases, sporadic forms of neurological diseases 
associated with protein aggregation are becoming much more prevalent [15].  For most, 
these diseases become the lethal element in their life.  There are different stages and 
anatomical locations of aggregation associated with each disease, but all are believed to 
begin with the transition of a properly folded native peptide to an aggregation-prone state.  
Alzheimer’s and Huntington’s diseases are two of many neurological diseases that are 
associated with protein aggregation.  The respective polypeptides, amyloid beta (Aβ) and 
the polyglutamine mutation (polyQ), are thought to seed aggregation by the formation of 
oligomers directly from this aggregation-prone transition state.  Both peptides are 
natively disordered, making them thermodynamically sensitive, and they are the major 
components of the larger inclusion bodies (large, insoluble, highly homogeneous 
aggregates) associated with each disease.  After death, the identification of these 
inclusion bodies, or plaques, during autopsy gives the definitive diagnosis of each 
disease.  Figure 1-1 depicts a cartoon to demonstrate the different possible ways in which 
the aggregates may affect cellular activities (left), and presents several real pictures of 








Figure 1-1. Artist’s depiction and real images of aggregates.  Left: A cartoon 
representation of the different aggregates that may form in Alzheimer’s disease.  Red W-
shaped species are dimers and trimers of Aβ that may disrupt synaptic efficacy (enlarged 
portion).  The larger amyloid plaques, also composed of Aβ, disrupt the cytoskeletal 
integrity of the astrocytes and microglial cell causing an immune response by the release 
of cytokines.  These plaques also disrupt the axonal trajectories.  The neurofibrillary 
tangles are composed of Tau protein and their formation may be protective against the 
damage caused by smaller oligomers, but this remains controversial.  Right:  
Photomicrographs of several different types of inclusion bodies seen as the dark regions, 
due to staining.  The plaques in each photomicrograph result from the aggregation of a 
different protein as in the other micrographs.  Bars in the lower right hand corner 
represent the following distances: (A) 40 µm, (B) 80 µm, (C) 12 µm, (E) 8 µm, (F) 80 
µm, (G) 40 µm.  Reprinted with permission from (left) [16] with permission from 
Elsevier, and (right) reprinted from Rossor, et al. Semantic dementia with ubiquitin-
positive tau-negative inclusion bodies. Brain. 2000. 123. p 267-276. by permission of 






1.2. Aggregate-Prone Peptides: Structure and Function 
Repeated studies have shown that both Aβ and polyQ mutated huntingtin protein 
(the protein involved in Huntington’s Disease) are involved with nerve cell function [18-
24].  These studies have demonstrated that the prefibrillar form of Aβ is associated with 
nerve synapse and learning, while huntingtin protein is linked to striatal neuron health.  
Specifically, huntingtin’s putative normal functions are vesicular transport, signaling, and 
transcription [24].  Therefore, these peptides are thought to have normal and necessary 
functions in their natively folded states, but may transition to an aggregation-prone state 
prior to aggregate formation.  Furthermore, it has been demonstrated that it is the 
oligomeric forms of Aβ that inhibit long term potentiation and not the monomeric [16].  
 
1.2.1. The Intermediate: Partial Unfolding as an Aggregation Prerequisite 
In an aqueous environment a completely folded peptide has its hydrophobic 
residues mostly buried eliminating the driving force behind aggregation.  On the other 
hand, a completely unfolded peptide is unordered in terms of hydrophobic and 
hydrophilic residues, this too reducing the tendency towards aggregation since 
hydrophilic residues would remain hydrated.  In the unfolded state the hydration of the 
hydrophobic residues is unfavorable and raises the free energy of the local water.  To 
reduce this unfavorable hydration effect, the peptide is driven to form intramolecular 
hydrophobic interactions, releasing water to the bulk (Figure 1-2).  These intramolecular 
interactions could result in a number of partially folded intermediates along the folding 





Figure 1-2. Hydration effects of water.  Here it can be seen that the availability of the 
solvent to form hydrogen bonds with the backbone plays a crucial role in intramolecular 
backbone bond formation.  Green shows favorable hydration and yellow unfavorable.  
Left shows an unfolded peptide with unfavorable hydration.  Right shows a folded 
protein with the release of water into the bulk.  Free energy of the system decreases from 
left to right in water but the direction may be reversed by addition of certain solvents and 
cosolvents that increase the free energy of bulk water.   
 
  
Figure 1-3. Energetic folding funnel and aggregation pathway.  Left:  Each pit in the 
folding landscape, above the native (N), represents a local energetic minimum where an 
intermediate is found.  Some of these pits may be aggregation-prone while others are not.  
Identifying those that are aggregation-prone may allow us to introduce a small solute or 
molecule that influences the peptide to follow a pathway that is not aggregation-prone or 
destabilizes those forms that are aggregation-prone, guiding them safely along the folding 
pathway.  Right:  A simplified model of the 3-dimensional folding landscape where many 
different aggregation-prone intermediates may exist.  N = Native, U = Unfolded, In = 
Multiple Intermediates that may exist, On = Multiple Oligomers that may exist, Lan = 
Multiple Large Aggregates that may exist (the subscript n represents the many different 
forms that may exist).  Each intermediate could take separate routes to the larger 
aggregates and some may never form oligomers or the larger aggregates.  It is possible 
that aggregation has a similarly complicated 3 dimensional landscape with pathways to 
many different aggregate forms, some of which are stable and some that are not.  
Energetic Folding Landscape (left) reprinted with permission from Macmillan Publishers 




hydrophobic core that may be transiently exposed to the solvent.  These contiguous 
hydrophobic residues provide the strong driving force behind aggregation, as every 
intermolecular hydrophobic contact reduces the free energy.  Small aggregates can form 
and go through further rearrangements to increase hydrophobic contacts and reduce 
unfavorable hydration.   As a result, soluble aggregates (oligomers) are produced that 
become the building blocks for the more highly ordered and stable beta structures of the 
different orders of aggregates [26].  Though oligomers and larger aggregates are bulky, 
the partially folded monomeric intermediates are not.  Intermediates and unfolded 
peptides can diffuse through the complex environment of the cell, and, since either 
unfolding or folding may form the intermediate, aggregation is further facilitated [13].  
As a consequence, peptides with higher native folding energies are more likely to be 
aggregation-prone because they are less stable and more likely to transition back and 
forth between the folded and unfolded states at physiological conditions. 
 
1.2.2. Nucleation, Aggregation, and Toxicity 
As stated above, the intermediate may form from either the folded or fully 
unfolded peptide.  As a consequence there may be multiple forms of intermediates that 
exist along both the folding and unfolding landscape.  The existence of multiple 
intermediates increases the chances that other destabilized peptides nearby may provide a 
complementary hydrophobic surface, driving aggregation and stabilizing the aggregate-
prone contiguous hydrophobic structure.  Once the aggregate-prone state has formed, it is 




destabilized proteins into a complementary aggregation-prone state [8].  Because these 
aggregation-prone peptides are natively disordered, after nucleation the aggregation 
process is thermodynamically favored to minimize the unfavorable hydrophobic protein-
solvent interactions [7]. 
Several different paths of aggregation have been demonstrated and are under 
debate [9, 27-31].  The path by which aggregation proceeds is of little consequence to 
this research, but it is important to note that each peptide may have different 
characteristic aggregation kinetics.  As a consequence, the rate-limiting step (RLS) may 
occur in many different places: intermediate formation, dimer formation, 
nucleation/condensation/growth, etc.  No matter, if the RLS is not the formation of the 
intermediate, then it must be down stream from it [32].  As a consequence, each 
neurodegenerative disease may be able to form different types of aggregates, some that 
may be benign and some that may be toxic.  There may be several soluble forms that are 
each uniquely stable and toxic and some that are unstable and disaggregate.  No matter 
the case, there is a strong correlation between neurodegenerative diseases and protein 
aggregation [16, 22, 26, 33]. 
It has been proposed that the formation of these soluble aggregates mark the onset 
of the associated disease and may also be most toxic in nature [34, 35].  A soluble 
aggregate may range in size from an oligomer, made up of just a few peptides and 
globular in structure, to the protofibrils that are larger and highly ordered.  Protofibrils are 
the immediate precursors to the full-fledged fibrils that are linear and extend up to 400 




neurofibrillary tangles (NFT) that are hallmark of each disease.  It has been demonstrated 
that intracellular protofibrils may be 100,000 times as toxic as their extracellular 
counterparts [37] and that they are able to embed into membranes creating permeable-
pores [36] that could depolarize the cell membrane.  Because of this toxicity, some 
researchers are asking if fiber formation is nature’s way to reduce the toxic effects of 
soluble aggregates [38-43].  If soluble aggregates are toxic and the toxicity is an 
intracellular event, then understanding this transition state becomes even more important, 
in a therapeutic sense, since the goal becomes the prevention of their formation instead of 
their removal before mature fibril formation.  It therefore becomes necessary to stop the 
formation of these aggregates at the source.  Whether soluble aggregates are the toxic 
species or not, they are still the precursor to the larger fibers and plaques that are 
hallmark to these diseases.  Most researchers do acknowledge that, as these fibers and 
plaques grow and amyloidosis sets in, there is irreversible damage to the nervous system 
as connections between nerve cells are disrupted and the cytoskeletal integrity is 
destroyed [39, 44, 45].  
 
1.2.3. Polyglutamine Diseases 
The polyglutamine diseases relevant to protein aggregation are caused by 
expanded repeat mutations in the coding region of the DNA sequence.  The trinucleotide 
(CAG) codon that encodes for glutamine is repeated within the DNA sequence.  Once the 
expansion exceeds a critical length of 35-45 repeats, the affected peptide is prone to 






Table 1-1. Details of polyglutamine diseases 
 
Disease  Gene      Protein  Localization   Putative normal function   Most affected regions   Common Symptoms 
 
SCA1  ATXN1      ataxin-1   Nucleus    Transcription    Cerebellar cortex, dentate nucleus,  Incoordination (hands,  
(interaction with corepressor SMRT)  brainstem, cerebral cortex  balance, swallowing,  
        dysarthria) 
 
SCA2  ATXN2      ataxin-2  Nucleus    RNA metabolism    Cerebellar cortex, brainstem,  Incoordination (hands, 
cerebral cortex   balance), Neuropathy 
(loss of feeling and  
reflexes) 
 
SCA3 ATXN3      ataxin-3   Nucleus    Deubiquitylating enzyme   Cerebellum, basal ganglia,  Incoordination (hands, 
brainstem, spinal cord   dysarthria, spasticity, 
   rigidity, muscular 
   atrophy, slowness) 
 
SCA6  CACNA1A     α1A  Cytoplasm    P/Q type α1A calcium channel subunit  Cerebellum    Incoordination (limbs, 
    voltage-dependent            tremors, dysarthria, 
    calcium channel            dysphagia) 
    subunit 
 
SCA7  ATXN7      ataxin-7  Nucleus    Subunit of TFTC/STAGA coactivator  Cerebellum, retina,   Visual Problems (color, 
complexes     brainstem, visual cortex  acuity), Incoordination  
       (eye movement, 
       dysarthria, dysphagia) 
 
SCA17  TBP      TATA box  Nucleus    General transcription factor   Cerebellum, striatum   Incoordination,  
    binding protein            Dementia 
 
HD  HD      huntingtin  Cytoplasm and nucleus  Vesicular transport, signaling, transcription  Striatum, cerebral cortex  Personality Changes, 
               Cognitive Decline, 
               Inccordination  
               (balance, limbs, face) 
 
SBMA  AR      androgen receptor  Cytoplasm and nucleus  Nuclear receptor    Spinal cord, brainstem   Muscle Weakness, 
               Abnormal Processing 
               of Androgens 
 
DRPLA  ATN1     atrophin-1  Nucleus    Nuclear receptor corepressor   Cerebellum, cerebral cortex,  Incoordination,  
basal ganglia, subthalamic nuclei  Dementia 
 





Each susceptible peptide (Table 1-1) has a different critical length [48].  In addition, a 
single mutation in the flanking sequence could affect the stability of the susceptible 
peptide.  Though in general, the translated peptides become more destabilized and 
aggregation-prone with the increasing number of repeats.  Several studies have shown an 
inverse correlation between expansion length and age of onset, and an increasing 
aggregate stability with expansion length [21, 24, 46].  Table 1-1, that gives anextensive 
list of polyQ aggregation diseases, lists two common functions that are emerging among 
proteins associated with polyQ diseases: transcriptional dysregulation and organelle 
dysfunction [23, 24, 48, 49]. 
 
1.2.4. Aβ and Alzheimer’s Disease 
Alzheimer’s disease (AD) is defined by the formation of neuritic plaques 
(amyloid deposits in the gray matter of the brain), and NFTs in the cerebral neuropil and 
vasculature [39].  Aβ peptides are a small fragment of a larger protein known as amyloid 
precursor protein (APP).  APP is a Type I transmembrane protein with its N-terminus in 
the lumen and C-terminus in the cytosol.  The N-terminus contains several sections that 
can be degraded into separate fragments, most of which are thought to have biological 
functions including neurite outgrowth, dendritic arborization, and synaptogenesis [22].  
Aβ is believed to be a functional component in many of these processes, specifically the 
following: surface reception, cell/substratum adhesion, neurite outgrowth, calcium 




function remains controversial, though more and more researchers are providing evidence 
as to its biological significance [18-20, 22, 34, 50]. 
Aβ is produced by the successive cleavage of APP by β-secretase at the N-
terminus and γ-secretase at the C-terminus [51].  Cleavage by β-secretase releases soluble 
APP leaving Aβ partially anchored in the lipid membrane.  Upon γ-secretase cleavage, 
Aβ is released into the lumen, and the APP intracellular domain is released into the 
cytosol.  Together these two peptides make up the component that traverses the lipid 
membrane, anchoring APP to the endoplasmic reticulum.  Aβ may be 39-43 amino acids 
in length, for which the C-terminus is the variable end except in certain familial versions 
of the disease [52].  The most common unmutated form, involved in sporadic 
Alzheimer’s, is 40 amino acids in length (Aβ40), but since the γ-secretase cleavage site is 
not definite, Aβ42 makes up a small population.  Each additional amino acid increases 
the hydrophobicity of the peptide, therefore influencing the aggregation kinetics.  In some 
familial forms, certain mutations within Aβ40 also increase the propensity to aggregate 
[38, 52, 53].   
A third enzyme, α-secretase, cleaves APP within the Aβ sequence preventing Aβ 
production and competes with β-secretase [54].  A mutation within α-secretase, 
inhibiting its enzymatic action, results in an over abundance of Aβ40, increasing its 
intracellular concentration.  Following the same reasoning, mutations within any one of 
the secretase enzymes result in improper Aβ processing.  This provides a rationale for 




destabilized and more aggregate prone due to a mutation(s) within the Aβ sequence.  (2) 
A mutation(s) with either Aβ or one of the secretases interferes with the normal 
processing of the peptide, producing a more aggregate-prone peptide.  (3) A mutation(s) 
within either Aβ or one of the secretases interferes with the processing of the peptide and 
produces an overabundance, increasing the Aβ concentration [22].   
To reiterate, AD cannot be reduced to a single pathological cause but instead has 
several that can be categorized as familial, those that facilitate Aβ assembly into 
aggregates, or sporadic, where an increase in Aβ concentration leads to aggregation [38].  
The pathology may be rooted in the genetic coding sequence for APP itself or within that 
for an external regulatory system involved with APP processing, such as the Wnt 
signaling pathway or presenilin-1 (PS) proteins [13, 26, 55].  This research investigates 
the unmutated Aβ40, and so is applicable to the more common sporadic versions of the 
disease, those due to the extended human life span.  
 
1.3. Review of Current Techniques in Peptide Aggregation Studies 
This study is focused on detecting the aggregation-prone intermediate state(s), 
which exists prior to aggregation, and on the folding pathway between the native and 
unfolded states.  Currently, no techniques have been successful at detecting and 
characterizing this (these) state(s).  In most of the current techniques the peptides are in 
solution, and since the intermediate states are able to quickly diffuse through even a 
crowded environment, the intermediates quickly aggregate before detection [13].  




and understand why these neurodegenerative diseases can vary from person to person in 
pathology, no technique for trapping intermediates has been developed.  A brief review 
of current techniques is given below with focus on those that may be capable of detecting 
the intermediate state. 
 
1.3.1. Analytical Techniques 
Current research on protein aggregation utilizes a multitude of techniques that is 
too vast to cover in this paper.  Table 1-2 in Section 1.3.1.1 was given in a review by 
Wang [13] and summarizes some of the more practiced techniques. 
 
1.3.1.1. Detection of the Intermediate 
Several of the analytical techniques listed in Table 1-2 have the potential of 
detecting the intermediate state if aggregation could be prevented.  Differential Scanning 
Calorimetry (DSC) in conjunction with light scattering and/or spectroscopy has the 
potential to provide valuable information about the intermediate state.  DSC gathers 
information about the energetics of the folding/unfolding pathways, light scattering gives 
information about size and shape, and spectroscopy can provide information about the 
structural content and changes [13, 76]. 
The thermal folding and unfolding of a peptide is well understood.  DSC is 
capable of measuring the heat absorbed by a peptide by measuring the difference between 
the sample cell and a reference cell containing the same buffer.  The cell temperatures are 




Table 1-2.  Analytical techniques in characterizing protein aggregation 
 
Categories  Individual techniques   Applications   Protein examples  References 
 
Calorimetry  DSC    Thermal protein  FVIII SQ   [56] 
unfolding/aggregation 
 
Centrifugation  Analytical centrifugation  Size and shape estimation  Insulin   [57] 
 
Chromatography  SEC-HPLC   Size estimation and  Factor IX   [58] 
quantitation 
hGH   [59] 
RP-HPLC    Isoforms of aggregates  bFGF   [60, 61] 
 
Electrophoresis  SDS-PAGE   Size estimation and  aFGF   [62] 
mechanistic probing 
Native PAGE   Aggregation process and IL-2   [63] 
mechanistic probing 
 
Light scattering  Static light scattering   Size and shape estimation  β-Amyloid peptide,  [64] 
β1–40    
Insulin   [65] 
Dynamic light scattering  Size distribution of soluble Deoxy hemoglobin  [66] 
aggregates 
Light scattering/obscuration  Size estimation and relative Deoxy hemoglobin  [66] 
distribution 
 
Rheology   Dynamic shear rheometry  Gelation characterization  BSA   [67] 
 
Spectroscopy  CD    Aggregation process   Interferon-γ  [68, 69] 
Fluorescence   Aggregation process   α1-Antitrypsin  [70] 
IR    Aggregation process   β-Lactoglobulin, etc.  [71] 
NMR    Aggregation process   CspA   [72] 
UV–vis    Soluble and insoluble  aFGF   [73] 
aggregates 
 
Microscopy  Light microscopy   Shape and size determination  Immunoglobulin [74] 
mutants    
Electron microscopy   Shape and size determination β-Amyloid peptide  [12] 
Atomic force microscopy  Shape and size determination  β-Amyloid peptide  [75] 
 
Table reprinted from [13] with permission from Elsevier. 
 
landscape is capable of providing valuable information about the changes in the 
intramolecular contacts as the peptides transition through the intermediate(s) state(s).  
The intermediate states could be identified by changes in the absorption landscape 
indicating semi-stable folding states.  One shortcoming of DSC is that it is not capable of 
providing information about the secondary structural content or even the general size and 




As the peptides transition from the tight globule form of the native fold to the 
long linear molecule of the unfolded state, the radius of gyration changes.  Light 
scattering is able to monitor this structural transition.  In this technique, collimated light 
is shown through a sample.  When the light comes into contact with the large peptides, as 
compared to the wavelength, the light is scattered and the angle can be measured.  By 
measuring the intensity and angle of the scattered light, information about the size and 
shape of the peptides may be calculated.  The limit to this method is that only information 
about the size and shape is obtained and not the secondary structural content [13, 76]. 
Several spectroscopic techniques are capable of providing unique secondary 
structural information.  Nuclear magnetic resonance (NMR) provides information about 
specific bonds made along the peptide backbone.  The spectra returned gives signals that 
are correlated to each other, providing information about which residues are involved in 
hydrogen bonds with each other or the solvent, and that may be protected from 
interacting with the solvent.  Any element with a non-zero total nuclear spin will feel a 
force from an external magnetic field, and whether that field is made by a neighboring 
element or an external man made electromagnet does not matter.  It is the neighboring 
atoms’ fields that correlate the signals, and it is the external field that induces the atoms 
to first align, and then flip, creating the spectra.  Infrared spectroscopy (IR) is an 
absorption technique where the spectra signals’ sizes, positions, and shapes are 
characteristic of specific bond types.  The light absorbed is changed into vibrational 




precise/quantitated energy that is original and characteristic to the type of bond and the 
elements involved [13, 76]. 
In summary, DSC can identify semi-stable intermediate states, light scattering 
provides information as to the size and shape, and spectroscopic techniques allow one to 
estimate the secondary structural content.  Still, all of these methods suffer from the 
tendency of the peptides to aggregate out of solution before the intermediate state can be 
detected.  As a consequence, these analytical techniques are capable of detecting the 
intermediate only if an experimental technique that prevents aggregate formation is 
available. 
 
1.3.2. Experimental Techniques Used in Protein Studies 
1.3.2.1. Solution Methods 
In solution experiments, peptides are usually brought up in 1 – 10 mg/ml 
concentrations in aqueous buffer.  The solubilized peptides are stabilized by favorable 
peptide-water interactions that keep the hydrophobic portions of the peptide buried in the 
interior.  The advantage of this method is the intrinsically low free energy and strong 
hydrophobic effect of water properties in a solution environment on the structure of the 
soluble peptide.  Evolutionary pressure should have ensured that the cellular environment 
was at or lower than the free energy of neat water, thus stabilizing cellular membranes 
and other hydrophobically driven interactions vital to a living organism [13, 77].  Once 
the peptides in solutions are destabilized, either thermally or chemically, the hydrophobic 




core, the peptides quickly aggregate out of solution, and the intermediate cannot be 
detected.  Because a small sub-population of the peptide is always in an intermediate 
state, aggregation still occurs on a larger timescale.  So, even in solutions where the 
peptides are thought to be stable, aggregation is a major concern.    
One way to overcome aggregation is to use fusion proteins.  In this technique, the 
aggregation-prone peptide’s sequence is inserted into a larger soluble protein’s sequence.  
By performing the same experiments on both the fusion protein and the larger soluble 
protein, absent of the aggregation-prone peptide, data from the latter can be treated as 
background.  Two such studies were preformed by Otzen et al. 2004 [78] and Konno 
2000 [79] who both were investigating Aβ and its ability to induce aggregation in a 
soluble protein.  A third by Masino 2002 [80] investigated the structures of different 
expansions of polyQ repeats.  Unfortunately, there is no way to rule out that these two 
fused polypeptides affect each other’s stability and structure, and they most likely do.  
Therefore, both peptides may have context-dependent structures, so that the background 
spectra is not representative of the structure in the fusion peptide, and so that the 
aggregation-prone portion may be different structurally, making interpretation difficult. 
 
1.3.2.2. Crowding Agents and Excluded Volume 
To mimic the peptides’ natural environment, crowding agents are added to 
solutions that are treated in a similar way to the solution experiments.  Crowding agents 
add effects absent in solution experiments.  These are excluded volume effects and a 




chemistries and their interaction with water [81].  These effects create several competing 
biophysical effects: (1) The rate of diffusion is decreased because two molecules cannot 
occupy the same space and pass through each other.  (2) The peptides’ entropy is 
decreased because there are fewer ways for the molecules to be arranged, which in turn 
increases the total conformational free energy.  (3) The effective concentration is 
increased due to the excluded volume [81].  These three conditions compete with each 
other.  The decreased diffusion rate slows peptide interaction and therefore slows 
aggregation.  The decrease in entropy induces a driving force to reduce the total excluded 
volume and increase the ways the molecules can be arranged.  As a result, both the 
collapsed globular native fold and the aggregated states are favored, competing to 
increase and reduce aggregation.  Therefore, the state that excludes the least total volume 
to surrounding macromolecules is favored.  And the increase in concentration increases 
the likeliness of interaction and therefore increases the rate of aggregation.  Factoring in 
the additional influence of the crowding agent’s surface chemistry on the structure/free 
energy of the bulk water, a very complex thermodynamic environment is created that 
should be much closer to the environment in vivo.  As a consequence, the choice of the 
wrong concentration and type of crowding agent could accelerate aggregation [40, 41].  
Regardless of whether these effects work to increase or decrease the peptides’ stability, 
the intermediates are still able to diffuse easily through the medium and may aggregate 






1.3.2.3. Experiments In Vivo 
 The natural environment of a living system is the only way to truly reproduce the 
intermediate structures responsible for the aggregation involved in neurodegenerative 
diseases.  Unfortunately, current methods of study, such as in-cell NMR or fluorescence, 
are only able to detect large populations.  Since the aggregation-prone state exists only 
transiently and in small populations during aggregation, these methods are limited to 
detection of either the aggregation-resistant folded peptide or the larger aggregates.  The 
obvious consequence of these limitations is that detection of the intermediate is nearly 
impossible. 
 
1.4. Project Goals and Rationale 
The purpose of this work is to successfully encapsulate two aggregation-prone 
peptides, Aβ and polyQ, in a sol-gel matrix so that they are isolated and prevented from 
aggregating, to characterize this novel system by comparing the samples to solution 
experiments, and to identify the aggregation-prone intermediate/transition states along the 
folding/unfolding pathway and the environmental factors that lead to it.  Additionally, we 
hope to introduce a particle small enough to penetrate the sol-gel matrix that can either 
stabilize or bypass the intermediate, avoiding aggregation. 
Numerous studies have shown that the partial unfolding of proteins, which are not 
normally amyloidogenic, can lead to aggregation, making partial unfolding an 
aggregation prerequisite [82].  Both Aβ and polyQ are believed to be natively 







Figure 1-4. Protein aggregation from native state to disease-associated plaques. 
Aggregation-prone peptides are thought to have a useful purpose in a living organism and 
therefore must have a native state.  These peptides may be destabilized by an unknown 
influence and transition into an aggregation-prone state known as the transition state.  If 
these transition state peptides come into contact with another destabilized peptide, 
aggregation may proceed, and an oligomer is produced.  These oligomers grow by 
contacting other oligomers or destabilized peptides, eventually becoming a protofibril.  
Protofibrils are large soluble aggregates and continue to grow into the insoluble fibrils, 
which eventually become the plaques associated with disease.  This research focuses on 
identifying the transition state with the intent on discovering the conditions that cause it 
and prevent it.  We focus our work on the change represented by the double-headed 
arrow above, so to stop aggregation all together. 
 
 
their folding/unfolding transition.  As a result, slight thermodynamic variation can cause 
these peptides to partially unfold, exposing their hydrophobic core to the solvent, and 
aggregation to occur at physiological conditions [83].  To study this transition the 
peptides will be encapsulated in a sol-gel matrix to prevent them from interacting and 
subsequently aggregating.  To ensure peptide solubility during gelation a 10% 3,3,3-
trifluoropropyl-trimethoxysilane (F3-propyl TriMOS)/90% Tetramethoxysilane (TMOS) 
glass will be prepared.  The F3-Propyl TriMOS is known to increase the peptides’ helical 
content, therefore increasing solubility [84]. 
                          











One of the major benefits of this method is that the glass sample can be reused 
and reversibility can be tested.  Because both phases of the sol-gel environment are 
continuous, a sample can be equilibrated in one solution, the spectra can be taken, the 
sample can be removed, rinsed and placed into a new solution.  This technique gives the 
obvious advantage of testing for intermediates along both the folding and unfolding 
landscape, determining if they are the same intermediates, and observing how these 
peptides are affected by the initial conditions. 
To test the folding landscape, the solvent conditions can be controlled by 
adjusting the pH, potassium phosphate (KPhos) concentration, fluorinated alcohols 
concentration, and temperature.  It has become widely accepted that peptide solubility is 
a function of its surface charge, hydrophilic content, and secondary structural 
arrangement.  The surface charge content is a function of the pH.  By altering the pH, the 
net ionic charge of the solution is adjusted and the peptide’s net charge is altered, causing 
it to change structure and affecting its solubility.  Salt concentration affects a peptide’s 
solubility in a similar way.  Fluorinated alcohols are known to induce helical structure, 
increasing a peptide’s solubility with increasing alcohol concentration.  Increasing 
temperature can increase peptide solubility to a certain point where the peptide begins to 
unfold.  If the temperature is raised slowly enough, aggregation may occur but is more 
likely to occur during the refolding step when the temperature is reduced and smaller 
aggregates survive the thermal refolding threshold.  As the temperature is increased, even 




peptides’ structures and test the widely used hypothesis that these peptides partially 
unfold, losing secondary structure, and form a semi-stable intermediate [14]. 
Understanding the intermediates’ structures and the pathways between their 
formations has many potential benefits, one of which would be the development or 
discovery of a solute that could interact with the intermediate preventing aggregation.  
Another outcome could be the development of a method of detection to determine the 
concentration of certain types of aggregation-prone peptides in vivo so a diagnosis of 
these diseases could be made before death.  Understanding protein aggregation as 
applicable to neurodegenerative diseases may also lead to the understanding of other 
aggregation phenomena, both desirable and undesirable, e.g. drug development and 
storage (shelf life -- introduce a stabilizing agent), materials engineering [76, 83]. 
 
1.5. Introduction to Analytical and Experimental Techniques Used in this Study 
1.5.1. Circular Dichroism Spectroscopy 
Circular Dichroism (CD) Spectroscopy is a technique where equal amounts of left 
and right-handed circularly polarized light are independently passed through a chiral 
(asymmetric) sample.  The absorptions are measured and a difference spectrum is 
reported.  A chiral sample, such as a peptide, will absorb each handedness differently 
because it is not superimposable on its mirror image and can never be oriented in the 
same way to interact with both polarizations of light [76] (Figure 1-6). 
A peptide is built as a linear arrangement of amino acids and is capable of taking 




The first two, α-helical and β-sheet, are due to organized hydrogen bonds between the 
carbonyl oxygen and the amide hydrogen along the peptide backbone.  An arrangement 
of these bonds, 3.6 residues apart, makes up the coiled structure of the α-helix.  A β-sheet 
is formed when the peptide backbone passes by itself in a linear manner and forms these 
hydrogen bonds between two parallel or antiparallel chains.  These two organized 
structures stress the bonds adjacent to alpha carbon (Cα, chiral center) in a specific way 
and determine the wavelength of light each bond can absorb (Figure 1-7).  The third 
category, random coil, is characterized by a lack of repetitive secondary structure.  
Statistically, random coil is considered an ensemble of conformations of the same peptide 
and is not considered to be symmetric [4].  This asymmetry does not mean that the φ and  
 
 
Figure 1-6. Circular dichroism.  Left and right-handed circularly polarized light is 
transmitted through a chiral sample.  The difference between the two absorptions (∆A) is 







Figure 1-7. Peptide backbone transitions.  The intensity and energy of the indicated 
transitions depends on φ and ψ angles (i.e., secondary structure).  Transitions are centered 




ψ angles shown in Figure 1-7 are completely random, but are instead restricted by steric 
constraints and statistically take on one of three combinations, giving a distinct CD 
spectrum [76].  Figure 1-8 gives sample CD spectra for these three secondary structures, 
and Figure 1-9 shows the instrument used in this study. 
In summary, CD provides a powerful tool for determining the average secondary 
structural content over a population of the same peptide.  Even for a peptide that takes on 
combinations of these three structures, with a little knowledge of the nature of the 
peptide, a trained eye can interpret the composite spectrum.  Additionally, by monitoring 
the changes in the spectra, as conditions are changed, much information about the 
structural changes can be gained.  Even when interpretation is difficult, powerful 
deconvolution programs have been developed to calculate the percentage of each 
secondary structure present in each spectrum. 
 
 
π -> π* ~ 190 nm & 210 nm 




n -> π* ~ 220 nm 






Figure 1-8. CD spectra of pure secondary structure.  Alpha (α) helix is formed by 
repeated hydrogen bonds between the amide and carbonyl groups 3.6 residues from one 
another along the peptide backbone.  Similarly, a beta sheet is formed by hydrogen bonds 
formed by parallel or antiparallel chains with the distance between residues being 
variable.  Random coil possesses no structure except that inherent in the local interactions 
[85-87].  The dotted line at 200 nm indicates the minimum wavelength taken for the 
results presented within this thesis.  The vertical axis reports ellipticity that results from 
the difference spectrum explained in Figure 1-6.  Left: (CD Curves), reprinted with 
permission from [88].  Right: Arrows point from secondary structures found in an actual 










1.5.2. Sol-Gel Encapsulation 
The name sol-gel combines two terms: “Sol” meaning solid particles in a liquid, 
and “Gel” meaning an agglomeration of sol particles extending throughout the solution.  
Both the solution and gel phases are continuous throughout.  The glass phase is highly 
porous (Figure 1-10), trapping larger molecules within and allowing the smaller 
permeable solutes to be changed.  Two reactions drive the formation of the glass phase, 






           ≡Si – OR + H2O  ↔ ≡Si – OH + ROH (1) 
← Dehydration 
 
Alcohol Condensation → 
  ≡Si – OR + HO – Si≡   ↔ ≡Si – O – Si≡  + ROH (2) 
← Alcoholysis 
 
Water Condensation → 




Figure 1-10. Sol-gel cross section.  Sol-gel provides a porous environment that isolates 
the proteins.  Both solid and liquid phases are continuous allowing the solution to be 




These reactions allow for protein-compatible conditions during gelation, 
preserving peptide structure and function [81, 89, 90].  Because hydrolysis is the rate 
limiting step and must occur before either condensation step can proceed, the solution is 
made slightly acidic to catalyze the reaction, before the peptide solution is added.  The 
peptide can be brought up in a wide variety of solutions in which it is soluble, usually a 
buffered solution near physiological pH that initiates the condensation reactions.  There 
are two notable shortcomings to the encapsulation approach.  (1) The glass matrix starts 




is lost, making deconvolution of the CD spectra less reliable.  (2) The peptide may be 
adsorbed to the silica surface and may alter the CD spectrum due to altered protein 
structure [91]. 
 
1.5.2.1. Thermodynamic Considerations in the Glass Matrix 
 Important and often neglected in peptide research are the effects of excluded 
volume, the peptides’ interactions with surrounding surfaces, and the influence these 
surfaces have on the solutions [81].  As discussed in section 1.3.2.2, the excluded volume 
effect has important thermodynamic consequences on the peptide’s structure, function, 
and interactions.  A paper by Ellis [90] estimates the total protein and RNA concentration 
in Escherichia coli to be in the range of 300 – 400 g/l, making the total occupied volume 
20 – 30% of the cell.  In the sol-gel-derived environment it was shown that, after 
supercritical drying of the solvent, the silica’s total volume was 14% of the total volume 
[89].  Though this is significantly less excluded volume then the cellular environment, it 
was shown that in the glass matrix the conformational sensitivity of apomyoglobin is 
increased to many solutes relative to soluble apomyoglobin behavior in the same 
solutions [92].  Further study showed that, even though there was no correlation between 
pore size and protein structure, the incorporation of 5% monosubstituted alkoxysilanes in 
the silica increased the helical content of apomyoglobin with increasing alkyl group chain 
length [89].  Therefore, the glass surface and choice of incorporated modifiers have a 
significant influence on peptide structure.  This influence may be adjusted by changing 




1.6. Literature Review of Key Peptides 
1.6.1. Recent Studies on PolyQ 
 Solution studies of polyQ structure suggest a two-state isodichroic helical-random 
coil transition while in monomeric form and a beta sheet secondary structure for small 
soluble aggregates [80, 93-97].  Altschuler and coworkers [95] solubilized two polyQ 
stretches of 9 and 17 residues by flanking them with alanine and lysine rich residues, a 
modification known to promote helical structure.  These model peptides were 29% and 
50% polyQ, respectively.  The CD spectra showed increasing helicity with increasing 
TFE concentration and an isometric point near 203 nm for both peptides, indicating a 
two-state folding transition.  Studies by Perutz and coworkers [96] and Sharma and 
coworkers [97] confirm that small soluble aggregates take on beta structure that Perutz 
had previously termed polar zippers [98].  Both of these studies also suggest that a 
hydrogen bonded hairpin turn exists within the soluble monomeric form.  It should be 
noted that Perutz used the same peptide sequence tested in this thesis. 
A study by Darnell et al., 2007 [93], demonstrates that the length of the repeat is 
also a factor in oligomer formation.  Figure 1-11 shows the CD spectra and size exclusion 
chromatography (SEC) spectra from this study, demonstrating that the shorter repeat 
lengths appear random coil in structure and elute with one peak at the monomer’s 
estimated molecular weight, whereas the longer repeat lengths appear beta in structure 
and elute as larger multiple peaks, indicating the presence of oligomers.  Furthermore, it 
can be seen that the flanking amino acids are a factor in the formation of oligomers.  




form oligomers, and the structures these peptides take on are influenced by the flanking 
residues.  This influence is seen in the lower CD spectra of Figure 1-11 were all the 
peptides that are flanked by 11 prolines taken on, what the authors have termed, a 
polyproline type II-like structure; an “open” helix lacking internal hydrogen bonds.  
What’s notable is the similarity of this spectrum to that of a random coil spectrum, and 
that the longer polyQ repeat lengths still elute as a series of peaks indicating the presence 
of oligomers and the possible influence of the flanking sequences on the oligomer’s 
structure. 
Most studies, as in this thesis, utilized flanking sequences to increase solubility in 
solution.  One study by Walters and Murphy [94] went a step further to incorporate an 
interrupting sequence within the polyQ repeats.  This experiment was done to compare 
secondary structure, obtained by CD, with rates of aggregation, analyzed by SEC and 
sedimentation kinetics.  The following polypeptide was used, K2WQ10XXQ10AK2, where 
XX is the interrupting sequence.  The interrupting sequences were chosen because of 
their ability to induce specific structures, as described by the authors: Pro-Pro (PP) 
extended conformation, Ala-Ala (AA) lack of influence, and D-Pro-Gly (PG) beta 
inducing.  These were to be compared with a control polypeptide where the interrupting 
sequence had been deleted, termed Q20.  The CD spectra and aggregation kinetics for 
these samples can be seen in Figure 1-12.  All samples returned spectra indicative of 
random coil/helical structure, and aggregation rates were inversely proportional to the 
200 nm CD signal intensity.  In addition, all samples were shown to develop soluble 






Figure 1-11. CD and SEC of flanked polyQ sequences.  CD (left) and SEC (right).  CD: 
(a) Displays data for the indicated polyQ repeat lengths, flanked by the indicated amino 
acids to increase solubility, without the proline repeats.  (The same identification of 
peptide sequence in (a) and (b) may have been used to compare upper and lower figures, 
but (a) does not contain the proline repeats.)  The short polyQ lengths of 3 (red) and 6 
(blue) residues both return random coil spectra whereas the longer lengths of 9 (green) 
and 15 (black) give typical beta sheet spectra with a local minimum at 218nm.  (b) 
Flanking proline repeats were added to the sequence.  All return, what the authors term, 
polyproline type II like structure.  SEC: (a) Demonstrates that the longer polyQ repeats, 9 
and 15, both elute with multiple peaks, indicating the presents of oligomer, whereas the 
smaller two peptides have a single strong peak, indicating they are monomeric.  All 
samples were brought up in 10 mM sodium phosphate (NaPO4) (pH 7.0 – 7.3).  Reprinted 








Figure 1-12. Comparison of interrupted polyQ CD spectra to aggregation kinetics.  CD 
(left):  All spectra appear primarily random coil.  The PG sample was proposed to contain 
some beta structure by the authors and the PP was said to be extended.  Aggregation 
kinetics (right):  (a) After sedimentation, the supernatant was analyzed by SEC for the 
monomer.  (b) After sedimentation, the total soluble peptide was determined by taking 
the ratio of the supernatant to an uncentrifuged sample using bicinichoninic acid assay.  
Reprinted from [94] with permission from Elsevier. 
 
 
1.6.2. Recent Studies on Aβ 
 Like polyQ, several studies have proposed that Aβ is monomeric when in a 




addition, these studies have shown a conformational dependence on pH, with all studies 
in agreement that the percent composition of beta structure and the rate of aggregation are 
highest around the isoelectric point of approximately pH 5.5 [102].  Figure 1-13 [101] 
shows the CD spectra for the pH dependence of three different lengths of Aβ: Aβ(1-28) 
the extracellular charged domain, Aβ(1-39) related to sporadic Alzheimer’s, and      
Aβ(1-42) found in both sporadic and familial cases.  In panels (a), (b), and (c), TFE was 
added to the indicated ratio to induce helical structure, enhance solubility, and to see if 
the peptide still took on the most beta structure around the isoelectric point.  In panel (d), 
absent of TFE, it can be seen that the spectrum at pH 5.0 is weak, indicating insoluble 
aggregates have formed.  Comparing the three panels with TFE, it is evident that helical 
structure is weakest near the isoelectric point, but the authors also propose that there is 
some beta structure in panels (a) – (c).  The spectral shapes alone make this proposal 
debatable since panels (a) and (b) both have flattened regions between 220 and 210 nm 
and in panel (c) the minimum is red shifted away from 215 nm.  Furthermore, how does a 
peptide interact with the solvent when 30 – 60% of it is not water, and do the pH values 
really represent proton concentrations?  It is obvious the TFE has some stabilizing effect 
to the peptide’s structure as compared to panel (d).  Figure 1-14 [100] gives the pH curve 
for the extent of aggregation after 2 days of Aβ(1-40) in solution.  Here the authors 
measured the amount of Congo red bound to the aggregate.  This study shows that 





Figure 1-13. Effects of pH on various Aβ segments.  (a) Aβ- (1-28), (b) Aβ- (1-39), and 
(c)/(d) Aβ- (1-42) in the indicated ratios of TFE:H2O at the indicated pHs. All solutions 
were buffered with 5 µM KPhos and then adjusted as needed.  Reprinted from [101] with 




Figure 1-14. Quantification of pH dependent Αβ aggregation.  Αβ(1-40) was allowed to 
sit in solution for two days after which the amount of aggregation was quantified by 
Congo red binding, ploted as Cb.  Buffers used: (pH 3.3) 14 mM acetic acid, (pH 4.7 – 
6.0) 100 mM Mes, and (pH 6.5 – 7.9) 100 mM KPhos.  On the ordinate axis uM is µM.  




 Aside from the structure being pH dependent, another study by Huo and 
coworkers [103], Figure 1-15, has shown that when Aβ(1−42) is brought up as a dilute 
concentration, it is initially random coil and shifts to the beta structure with time, which 
should be a natural transition for an aggregate-prone peptide.  In addition, this study 
showed that, if methionine 35 were oxidized to methionine sulfoxide, the random coil to 
beta structure transition is slowed, along with aggregation.  They also showed that 
methionine oxidation prevented protofibril formation and altered fibril morphology.   
 
Figure 1-15. CD spectra of Αβ(1-42) at 0.17 and 48 h in 50 µM KPhos pH 7.3.  The 
unoxidized peptide changes from random coil to beta where the oxidized remains stable.  




These changes in conformation transition and aggregation may be due to the fact that 
methionine sulfoxide is more hydrophilic than methionine, this promoting a stable 





2. MATERIALS AND METHODS 
2.1. Chemical Reagents 
 All reagents were diluted into Milli-Q purified H2O.  The Integral water 
purification systems is a MilliporeTM product that filters tap water producing ultra-pure 
water meeting European Union (EU) and United States Pharmacopeia (USP) standards.  
The system uses their Elix technology, which is an electro deionization system.  All 
references made to water or H2O, unless otherwise noted, will refer to Milli-Q purified 
H2O. 
 
Table 2-1. List of Chemical Reagents Used in this Study. 
Reagent Abreviation Company 
3,3,3-Trifluoropropyl-trimethoxysilane F3-propyl triMOS Gelest Inc. 
Cesium Hydroxide CsOH ACROS 
Hexafluoroisopropanol HFIP ACROS 
Hydrochloric Acid HCl Fisher Chemicals 
Phosphoric Acid H3PO4 Mallinckrodt 
Potassium Hydroxide KOH Fisher Chemicals 
Tetramethylammonium Hydroxide N(CH3)4OH Fisher Chemicals 
Tetramethylorthosilicate TMOS ACROS 
Trifluoroacetate TFA ACROS/EM Science 




Two model polypeptides, polyQ and Aβ, were obtained from AnaSpec and 




aspartates attached to the N-terminus and two lysines to the C-terminus.  The unmutated 
(but sporadic disease-associated) form of Aβ40 was used, having the following sequence: 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV.   
 
2.3. Solubilization of Peptides 
A protocol from Chen and Wetzel was adapted for this research [104].  The 
peptides were brought up in 1.5 ml of 50:50 TFA:TFE, using approximately 3.5 – 4.0 mg 
for solution experiments and 1 – 1.5 mg for sol-gel experiments (per cassette, and for 
xerogel experiments below).  The solutions were mixed by inverting several times and 
allowed to sit overnight in a 15 ml plastic centrifuge tube.  To dry, nitrogen gas was 
bubbled through the sample using a small glass Pasteur pipette at a rate of a few bubbles 
per second, usually for 1 –3 days.  The dried peptides were resuspended in 1.2 ml of 1.00 
mM TFA (for sol-gel) or H2O (for solution experiments), and repetitive pipetting was 
performed until the peptides no longer stuck to the bottom of the centrifuge tube.  These 
solutions were allowed to sit until they clarified indicating the peptide was dissolved, 
approximately 1 h. 
 
2.4. Sol-Gel Glass Encapsulation 
Three 15 ml centrifuge tubes each had the following added in order: 895 µl 
TMOS, 105 µl F3-propyl triMOS, 30 µl 0.04 N HCl, 214 µl H2O.  Each tube was 
sonicated in a Branson model 1510 sonicator in ice water for no less than 30 min.   F3-




ml volume of peptide solution (described above) was diluted to 4.65 ml with water.  A 
3.10 ml volume of the sol was combined with the diluted peptide solution making a final 
concentration of 0.129 – 0.194 mg/ml.   The tubes were inverted three times, taking care 
not to produce any trapped air in the solution, and transferred to a disposable 
electrophoresis cassette with 1 mm spacing (Novex/Invitrogen).  The cassette was 
covered with Parafilm and left at room temperature to solidify (~4-5 days), at which time 
approximately 1 ml of water was layered on top of the glass to prevent drying, and the 
cassette was moved to 4°C to age for no less than two weeks.  Any sample analyzed after 
this step, with no further processing, will be referred to as a “wet-aged glass.” 
 
2.5. Xerogels 
Wet-aged glasses were opened using a spatula to carefully break free the two 
sides of the electrophoresis cassette, and 1x2 cm samples were cut.  Water was used as a 
lubricant to slide each piece to a 10x10 cm piece of Parafilm.  The samples were patted 
down on each side with a tissue, and the Parafilm was also dried.  The Parafilm, with the 
samples, was placed flat inside a plastic storage container.  A second 10x10 cm piece of 
Parafilm was cut and stretched over the container making an air-tight seal.  One or two 
small pinholes, equally spaced, were made above each sample.  This container was then 
stored at 4°C for a minimum of two weeks or until the glass samples appeared to stop 
shrinking.  Starting with a wet-aged glass with dimension 0.1cm x 1cm x 2cm (height x 
width x length), the final dimensions of the xerogel were approximately 0.06cm x 0.6cm 




transferred to the bottom of a plastic Fisherbrand semicuvette that was tilted 
approximately 45° from the vertical, such that the sample lay flat against the lower side.  
To slowly rehydrate the sample, 30 µl of H2O was added on the lip inside the cuvette just 
above the sample (direct contact with water may cause cracking).  Samples were then 
covered with Parafilm with one small pinhole, and returned to 4°C for ~5 days before 
being analyzed.  The final peptide concentration was estimated to be 0.614 – 0.924 
mg/ml.   
 
2.6. Solution Experiments 
A 1:10 dilution of the solubilized peptide was preformed with different 
concentrations of HFIP, TFE, and phosphate buffers at various pH values.  KPhos 
solution experiments were prepared by a 1:10 dilution of the peptide stock solution with 
1.00 M, 50.0 mM, and 10.0 mM KPhos solutions at the desired pH.  This dilution 
resulted in final phosphate concentrations being 0.900 M, 45.0 mM, and 9.00 mM.  
However, solution experiments were compared to xerogel experiments in the 
corresponding phosphate buffers (1.00 M, 50.0 mM, and 10.0 mM).  Percent HFIP was 
calculated as volume per volume (v/v) and represents the true concentration for both 
solution and xerogel experiments.  Solution samples were stored in 3 ml centrifuge tubes 
at an initial concentration of 0.30 mg/ml over the course of the time dependent data 






2.7. Xerogel Experiments 
 Prior to analysis, xerogel samples were placed in 3 ml plastic cuvettes with 3 ml 
of solvent, covered with Parafilm, tilted, and incubated for 24 h at 25°C.  For solvent 
exchange experiments, after the initial spectra were taken, the sample was allowed to 
equilibrate for 1 h in the new solvent and then drained and replaced with a fresh volume 
of the new solvent.  This initial equilibration was done to reduce the amount of the 
previous solvent carried over in the xerogel matrix. 
 
2.8. CD 
An Aviv model 215 Circular Dichroism Instrument (New Jersey, USA) was used 
with 2 mm quartz cuvets (Starna Cells).  All data were collected in the far-UV region.  
Wet-aged glass/xerogel samples were placed in the cells with the same solutions in which 
they had been equilibrated with.  Prior to data collection, spectra of the cells containing 
only (fresh) solution were taken as background and were subtracted from the peptide-
containing sample’s spectra.  Unless otherwise noted, peptide solution spectra were also 
collected using the same 2 mm quartz cells.  In thermal stability experiments, the 
background was not subtracted from the single wavelength intensity but was subtracted 
from the complete wavelength scans that were taken at constant temperature.  All spectra 







3. RESULTS AND DISCUSSION 
3.1. Peptide Disaggregation and Solubilization 
A protocol developed by Chen and Wetzel [104] was adapted where TFE was 
substituted for HFIP.  Two steps were identified to be most crucial in the disaggregation 
and solubilization process.  First, visual clarity of the suspended peptides in 1:1 TFA:TFE 
(v/v) after vortexing was not an adequate indicator of complete dissagregation.  Peptides 
that sat at room temperature for only an hour after clarification in the TFA:TFE solution 
gave inconsistent results.  However, when the clarified solution was allowed to sit 
overnight at room temperature (~14 h), consistent results were obtained.  Second, when 
resuspending the dried peptide in TFA solution at pH 3, the peptide was not immediately 
soluble but the solution clarified if a period of repetitive pipetting was performed several 
times over the course of approximately 1 h.  In addition, the clarified and resuspended 
peptide should be allowed to sit at room temperature for no less than 30 min prior to the 
experiment. 
 
3.2. Sol-Gel Encapsulation 
This work utilized the sol-gel process to isolate aggregation-prone peptides in the 
porous environment.  Both the solid and liquid phases are continuous, allowing the 
solvent to be exchanged.  A standard protocol [105] adapted by Eggers and Valentine 
[89] was modified to prevent peptide aggregation during gelation.  Since fluorinated 
alcohols are known to induce helical structure in peptides, thereby increasing solubility, a 




of the solubilized peptides was performed using glasses made from 10% F3-propyl 
TriMOS and 90% TMOS precursors (v/v) (Figure 1-5).  In addition, since both Αβ and 
polyQ promptly aggregated in buffered solutions, the addition of buffer prior to gelation 
was deleted and the volume was replaced by H2O.   
 
3.2.1. Development of Xerogels to Minimize Peptide Leaching 
Initial experiments showed a uniform loss of signal with each successive analysis 
in time, during thermal experiments, and upon solvent exchange.  Leaching of the 
peptides through the wet-aged glass matrix was suspected, so a protocol for the 
preparation of xerogels (a more condensed form of the wet-aged glass) was developed.  
PolyQ was used to test the xerogel environment.  The peptide’s small size of 19 residues 
makes it susceptible to leaching and, therefore, ideal for testing.  Preliminary data 
indicated that there was little to no leaching of the peptide out of the xerogel matrix.  
Further study showed that leaching did occur, though to a lesser extent (details will be 
discussed below as appropriate to each result). 
 
3.2.2. Analysis of Wet-Aged Glasses vs. Xerogel Spectral Data 
As stated in section 2.5, the xerogel was estimated to be 22% of the wet-aged 
glass’s original volume.  This has two possible consequences that may affect the 
peptide’s secondary structure.  (1) The volume of the pore is decreased, possibly 
increasing excluded volume effects, or creating direct interactions between the glass and 




alkoxysilane that interacts with the solvent was increased, further stabilizing the soluble 
peptide by increasing its helical content and/or altering peptide adsorption to the silica 
surface.  To explore these possibilities, a series of identical experiments was performed 
on both wet-aged and xerogel glass samples.  Though not all samples were prepared 
simultaneously, they were prepared with an identical protocol and with only slight 
variations in the total mass of the peptide.  In addition, the peptide was always obtained 
from the same stock. 
 
3.2.2.1. Spectral Intensities and Curve Shape 
Preliminary analysis of wet-aged glass-encapsulated polyQ was performed using 
potassium (K+), cesium (Cs+), and tetramethylammonium (N(CH3)4+) phosphate buffers 
at 10.0 mM, 50.0 mM, and 1.00 M concentrations at pH values near 7.  The strongest and 
most stable signal was obtained when samples were equilibrated in 1.00 M KPhos at 
pH 6.8, so this buffer was chosen to test for any influences due to the increased density of 
the xerogel matrix.  A comparison of wet-aged glass to xerogel encapsulated peptides 
shows an increase in CD signal intensity for the xerogel with no noticeable effect on 
spectral curve shape.  This suggested that there were no additional effects on the 
peptide’s secondary structure in the xerogel environment (Figure 3-1), and that there was 
an increase in peptide concentration.  The blue curve gives the spectrum of the wet-aged 
glass encapsulated peptide, red the xerogel, and green an enhanced wet-aged glass.  The 
green curve was obtained by multiplying the wet-aged glass spectrum by a factor of 4.  




secondary structure, and suggested that an increase in concentration was due to reduced 
leaching in the xerogel.  This increase in concentration allowed for less peptide to be used 

























Figure 3-1. Comparison of wet-aged glass to xerogel encapsulated PolyQ.  Both wet-
aged glass (blue) and xerogel (red) samples were placed in 1.0 M KPhos pH 6.7.  The 
enhanced wet-aged glass spectrum (green) is that of the wet-aged glass multiplied by 4.  
The overlap of the enhanced wet-aged glass spectrum on the xerogel indicates that there 
is an increase in concentration with little to no effect on the peptide’s secondary structure. 
 
 
 The phosphate buffer cations were chosen because of their variable effects on 
peptide secondary structure, as predicted by the Hofmeister series [106].  In general, each 
cation should stabilize a peptide’s secondary structure in the following order: K+ < Cs+ < 
N(CH3)4+.  The wet-aged glass spectra in Figure 3-2 (top) do not follow this trend.  This 
failure to follow the trend was most likely due to enhanced leaching of the peptide.  
These ions have previously been observed, by the Eggers Lab, to induce leaching of other 























































Figure 3-2. Comparison of encapsulated polyQ wet-aged glass vs. xerogel and the 
leaching effects of phosphate buffers.  Top (wet-aged glass) and bottom (xerogel).  PolyQ 
in 10.0 mM KPhos, CsPhos, and N(CH3)4Phos buffers all at pH 7.  Both leaching and 
peptide stability increase as K+ < Cs+ < N(CH3)4+.  The wet-aged glass spectra decrease 
in this order indicating leaching.  In the xerogel spectra there is a structural enhancement 
from K+ = Cs+ < N(CH3)4+, which is in agreement with the Hofmeister series with 
N(CH3)4+ being the weakest kosmotrope, and K+ and Cs+ having very similar chemical 
properties in solution.  The overlap of the K+ and Cs+ spectra may indicate that leaching 




was only 19 residues, and because the intensity of the wet-aged glass spectra followed 
this trend, the loss of signal was most likely due to leaching.  The lower panel of Figure 
3-2 is for the same experiment using xerogel samples.  It can be seen that the spectra of 




Cs+ was not when compared to the K+.  These spectra demonstrate that the xerogel 
environment was superior under all solvent conditions due to reduced leaching and the 
favorable effects of the F3-propyl modifier on helical structure. 
 
3.2.2.2. Spectral Intensities as a Function of Time 
Spectra of the wet-aged glass encapsulated peptides demonstrated a uniform loss 















































Figure 3-3. Spectral intensities as a function of time in the wet-aged glass vs. xerogel 
encapsulated peptides in 1.0 M KPhos, pH 6.7.  Left (wet-aged glass) and right (xerogel).  
Wet-aged glass encapsulated peptides show a continuously weakening signal intensity 
over 1, 7, and 21 days.  Relative signal intensities are constant with wavelength, 
indicating no change in secondary structure and probable leaching.  Xerogel encapsulated 
peptides show a slight increase in the 222 nm signal intensity between 1 and 13 days, and 
no change between 13 and 35 days.  The slight increase at 222 nm may be due to a gain 




Because the general shape of each spectrum retained the same character as the one before 




leaching was the cause of signal loss.  Xerogels, Figure 3-3 right, returned spectra with 
stable signal intensities, indicating that leaching does not occur after more than a month. 
 
3.2.2.3. Changes in Signal Intensities as a Function of Temperature  
The thermal stability of polyQ is shown in Figures 3-4 and 3-5.  The loss of signal 
intensity at the end of cooling was not recoverable for either sample, confirming that 
leaching did occur, but the xerogel sample had a much-reduced percent loss of peptide, as 
expected.  Figure 3-5 shows the before and after CD spectra related to Figure 3-4 for the 
































































Figure 3-4. Comparison of wet-aged glass to xerogel encapsulated peptides at 222 nm as 
a function of temperature.  Left (wet-aged glass) and right (xerogel).  The wet-aged glass 
sample was stored in 10 mM KPhos for 2 days and a temperature step of 5°C was used 
between data points with an averaging time of 2 s.  The temperature was held at 90°C for 
1 min between heating and cooling.  The xerogel sample was stored in H2O for 10 days 
and a temperature step of 2°C was used between data points with an averaging time of 15 
s.  The temperature was held at 95°C for 5 min.  The background has not been subtracted 





slightly weaker intensity, demonstrating that leaching took place with little change in 
secondary structure.  Figure 3-5 shows that there is approximately a 33% loss of signal in 



















































Figure 3-5. Comparison of wet-aged glass and xerogel spectra at 25°C before and after 
heating cycle.  Left (wet-aged glass) and right (xerogel) (Figure 3-4). 
 
 
3.2.2.4. Leaching of Encapsulated Peptides upon Solvent Exchange  
During solvent exchange, a peptide’s structure may be altered as it adjusts to the 
change in the environment, and this may also affect its interaction with the silica surface, 
thereby inducing leaching under the right conditions.  To test the extent of leaching upon 
solvent exchange, not only must the sample be returned to the original solvent, but also 
the changes in secondary structure must be reversible so that changes in intensity can be 
related to changes in peptide concentration.  All wet-aged glass samples showed a loss of 
signal with each successive solvent exchange.  Xerogels demonstrated the ability to 




3.2.2.5. Leaching and the Internal Environment of Wet-Aged and Xerogel Samples 
As stated in section 1.5.2.1, there is no obvious correlation between protein 
structure, average pore size, and surface area [92].  In addition, the fact that leaching still 
occured in the xerogel suggests that the extent to which the pore had been reduced did not 
drastically affect the internal environment where the peptides resided.  This is further 
supported by the coincidence of the enhanced spectrum of the wet-aged glass and the 
xerogel spectrum (in Figure 3-1).  As a consequence, one may conclude that the peptides 
populated the same states in the same ratios, indicating the same structure but different 
concentrations.  One possible reason for the xerogel’s resistance to leaching could be the 
increased density of the F3-Propyl-triMOS modifier and its hydrophobic influence on the 
solvent.  It is well known that fluorinated compounds are hydrophobic [107].  The 
hydrophobicity of the F3-propyl group should alter nearby water’s structure, raise the 
solvent free energy, and influence peptide adsorption to the surface [91].  Most likely, 
reductions in pore size and the channels between the pores restricted the motion of the 
peptides and minimized leaching. 
 
3.3. Characterization of Xerogel Encapsulated Peptides 
To characterize the influence of the xerogel matrix on the peptides’ secondary 
structures, data were collected and compared for encapsulated peptides and peptides in 
solution.  Due to aggregation during experiments in solution and because only very rough 
estimates of the peptides’ concentrations after encapsulation could be made, only the 




were chosen as solvents because they are well understood and documented for their 
influence on peptide structure.  Additionally, because the 10% F3-propyl TriMOS was 
suspected to have some influence on peptide secondary structure, different concentrations 
of TFE and HFIP were used to determine the extent of this influence. 
 
3.3.1. PolyQ  
3.3.1.1. Percent HFIP Solutions 
Figure 3-6 compares the spectra for soluble polyQ in water and encapsulated 
























Figure 3-6. Comparison of xerogel encapsulated polyQ to solution CD spectra in H2O.  
To compare shapes, the xerogel spectrum has been reduced by estimating the value of the 




encapsulation.  Figure 3-7 gives the spectra for solution (top) and xerogel encapsulated 
(bottom) polyQ at 1%, 5%, 10%, 25%, 35%, and 50% HFIP in H2O (v/v).  The xerogel 
























































Figure 3-7. PolyQ in solution vs. xerogel encapsulated spectra in HFIP solutions.  Top 
(solution) and bottom (xerogel).  Percent HFIP in water (v/v) are indicated to the right.  
Xerogel sample at 1% - 10% HFIP show enhanced helicity as indicated by the ratio of 
intensities at 222 nm to 208 nm. 
 
 
solution.  This increase may be partially due to the 10% F3-propyl triMOS glass and 
partially due to the crowded environment.  The relative increase of the signal at 222 nm 
as compared to the signal below 210 nm is indicative of increased helical content, and the 




6).  A similar shape is seen when comparing the 10% solution spectrum to the xerogel 
spectrum in 0 – 1% HFIP, which suggests that the xerogel environment was similar to the 
10% HFIP solution environment.  Because the xerogel is made from the 10% F3-propyl 
TriMOS precursors, this is a likely situation.  Solution and xerogel spectra at higher 
percent HFIP are similar in shape, which is to be expected since HFIP is known to induce 
helical structure in peptides, and at these concentrations of HFIP, the influence of the F3-
propyl modifier on the spectral shape would be less pronounced.  Both solution and 
xerogel samples show the same trend of increasing helical content with increasing HFIP 
concentration, but the solution spectrum appears to reach maximum helicity at 35% 
HFIP, whereas the encapsulated sample became slightly more helical in 50% HFIP. 
 
3.3.1.2. Effects of KPhos Concentration 
In Figure 3-8, xerogel encapsulated peptides show an increase in helical structure 
with increasing phosphate concentration compared to solution, as indicated by the more 
intense 222 nm signal when compared to the signal below 210 nm.  In both cases, the 
samples at the two lower KPhos concentrations gave similar spectra, indicating that 
KPhos had little effect on the structure at low concentrations, and that the increased 
helical structure in the glass was likely due to the F3-propyl modifier.  The 1.00 M 
encapsulated sample gave a highly enhanced spectrum while the 0.90 M solution sample 
gave a negligible increase in the 222 nm signal.  Because there was little change in the 
0.90 M KPhos solution spectrum after 1 h (not shown) or after 24 h (shown in Figure 3-











































Figure 3-8. Xerogel encapsulated vs. solution polyQ in KPhos at several concentrations.  
Top: solution at the indicated concentrations.  Bottom: xerogel encapsulated at the 
indicated concentrations.  All buffers were at pH 6.9, except the 1.00 M and 0.90 M 
samples that were at pH 6.8.  Both panels also contain the spectra of control samples 
incubated in water.  Inset: Comparison of the minima intensities of the 50.0 mM and 
10.0 mM xerogel samples to the 1.00 M sample.  Signals were normalized to the 




data).  Additionally, the encapsulated spectrum in 1.00 M KPhos shows a relative 
increase in the 222 nm signal over the signal below 210 nm as compared to the other 








This data suggests that the encapsulated peptides were monomeric and do not form 
irreversible aggregates. 
 
3.3.1.3. pH Dependence in KPhos Buffers 
The pH-dependent structure of the samples shown in Figure 3-8 can be seen in 
Figures 3-9 to 3-11.  Solution spectra give similar random coil profiles for all samples, 
except the 0.90 M KPhos sample at pH 11.4 that could not be interpreted because of 
noise below 215 nm most likely due to the high concentration of PO43- (Figure 3-9).  This 
sample appears to have a slightly stronger signal at 222 nm, as compared to the others, 
which may also be due to the PO43- concentration and its strong kosmotropic affect.  
Xerogel samples show enhanced secondary structures compared to solution data in all 
cases and separate into 3 distinct pH dependent spectra (Figures 3-10 and 3-11).   
At 1.00 M KPhos (Figure 3-9), the signal intensities gave the following pH 
dependence: 6.8 > 11.4 > 4.1.  The sample with the strongest signal (pH 6.8) may be the 
result of the peptide having no net charge with its termini equally and oppositely charged.  
This should increase favorable hydration of the peptide and, with the high KPhos 
concentration, increase secondary structure.  It is also possible that the oppositely-
charged termini form a hairpin, as discussed in Section 1.6.1, and that there was a tight 
coiling induced by the KPhos.  Following the same reasoning, at pH 11.4 the peptide 
would have a net negative charge due to the aspartates (pKa 3.86), and at pH 4.1 a 
significant population of the aspartates were still protonated, giving the peptide a net 




the peptides at pH 4.1 and 11.4 and decreasing the influence of the KPhos, as compared 
to the pH 6.8 sample.  The increased intensity of the pH 11.4 over the pH 4.1 sample can 
be explained by the difference in the phosphate ion.  At pH 11.4 the phosphate ion is in 
the PO43- state, a strong structure enhancing kosmotrope, and at pH 4.1 it was in the 
H2PO41- state, a weak kosmotrope. 
 At the lower KPhos concentrations of 50.0 mM (Figure 4-10) and 10.0 mM 














































Figure 3-9. Comparison of pH dependence of solution to xerogel encapsulated for polyQ 
in 0.90 M and 1.00 M KPhos solution, respectively.  Top (solution) and bottom (xerogel).  
Solution sample at pH 11.4 became extremely noisy below 212 nm so data was not taken 







values the aspartates should have been mostly deprotonated, and so the peptide should 
have been more strongly hydrated.  The fact that these acidic samples showed the most 
secondary structure may be related to changes in the silica surface.  Under acidic 
conditions, the surface may have been protonated (more Si-OH groups relative to Si-O- 
groups), making it more hydrophobic as compared to at neutral pH samples.  Looking at 
the 10.0 mM KPhos samples in Figure 3-11, it can be seen that the sample at pH 6.9 had 

















































Figure 3-10. Comparison of pH dependence of solution to xerogel encapsulated for 
























































Figure 3-11. Comparison of pH dependence of solution to xerogel encapsulated for 




the hydrophobicity of the glass surface leads to an increase in the secondary structure of 
peptides [84].  This observation may explain why the acidic samples showed the most 
secondary structure relative to other pH values at lower KPhos concentrations.  At these 
same KPhos concentrations, the basic samples (pH ~11) may display the least amount of 






well above lysine’s pKa, and so the peptide should have had a net negative charge, 
decreasing favorable hydration. 
 The failure of the solution samples to show any pH dependence, and the fact that 
they all return similar spectra at each concentration, may indicate that the peptide had 
formed stable soluble oligomers in solution.  Alternatively, one may attribute the more-
structured peptide in the glass to be the result of crowding and the chemistry of the silica 
surface.  Peptides appear to be more sensitive to solvent conditions when confined in this 
environment.  This observation is significant because information not seen by standard 
solution methods is obtained by sol-gel encapsulation. 
 
3.3.2. Aβ 
3.3.2.1. Percent HFIP Solutions 
A comparison of the pure water spectra for both solution and xerogel samples are 
presented in Figure 3-12.  The encapsulated peptide had a weakly enhanced secondary 
structure as indicated by the increased intensity between 210 nm and 225 nm.  Though 
there was an increase in secondary structure, the signal below 210 nm indicates that the 
sample was still largely random coil.  This increase in secondary structure may have been 
due to excluded volume, the modifier, or both.   
The spectra for Aβ peptide in solution and xerogel for different percent HFIP/H2O 
solutions (v/v) are given in Figure 3-13.  In solution, the Aβ 1% HFIP spectrum is still 
indicative of a random coil structure.  At 5%, Aβ began to take on secondary structure, as 




xerogel spectrum in H2O (Figure 4-12).  Deconvolution of this spectrum by CDNN 
























Figure 3-12. Comparison of xerogel encapsulated Aβ to solution CD spectra.  The 
increased intensity at 222 nm and the decreased intensity at 200 nm indicate that in the 




this spectrum was highly stable with time, indicating that it did not form large insoluble 
aggregates.  In either case, the peptide had taken on increased secondary structure, which 
is even more apparent in the spectra at 10% and above where significant helical structure 
can be seen.  It is also notable that at 50% HFIP there was a drop in intensity as compared 
to the 25% and 35% HFIP spectra. 
 Xerogel encapsulated Aβ showed a general increase in secondary structure with 
added HFIP up to 10% HFIP, as compared to that seen in solution (Figure 3-13).  The 
xerogel encapsulated spectra at 1% and 5% HFIP take on increased secondary structure 
relative to water.  As the HFIP concentration was increased, some beta character 




wavelengths.  At 25% HFIP, the spectra began to flatten out between 210 nm and 225 nm 





















































Figure 3-13. Aβ spectra in solution vs. xerogel.  Top (solution) and bottom (xerogel).  
Percent HFIP in water (v/v) are indicated to the right.  Inset (top): Aβ in 5% HFIP 
solution.  Inset (bottom): xerogel encapsulated Aβ in 1%, 5%, and 10% HFIP left 




Figure 3-13 shows a similar experiment when the samples were left at room temperature 
during a summer night and there was an approximate 10°C fluctuation in temperature.  
















findings, these samples showed significant beta structure at the lower HFIP 
concentrations.  It can be seen in the inset that there was a slight increase in secondary 
structure at 10% HFIP.  By comparing the panel to the inset, this increase is most likely 
due to an increase in helical structure.  Furthermore, the similarity between both 10% 
spectra (panel and inset) suggested that beta structure in the 10% HFIP spectrum was 
probable. 
 
Table 3-1. Deconvolution of soluble Aβ peptide in 5% HFIP solution. 
  200-260 nm 205-260 nm 210-260 nm 
Helix 28.00% 33.80% 31.80% 
Antiparallel 10.70% 7.80% 8.70% 
Parallel 9.50% 8.90% 9.10% 
Beta-Turn 18.30% 16.70% 17.20% 
Rndm. Coil 32.60% 32.80% 34.10% 
Total Sum 99.20% 100.00% 100.80% 
Top column gives the wavelength range over which the program used to  




The changes in secondary structure of the encapsulated samples in 1 – 10%  
HFIP cannot be attributed to the F3-propyl modifier alone because of the significant 
differences in the glass spectra as compared to the solutions.  Aβ was about twice the size 
of the polyQ peptide but still small compared to an average globular protein.  
Nevertheless, excluded volume effects might have had more of an influence on Aβ’s 
secondary structure.  The different amino acid composition of Aβ relative to polyQ might 
also have changed the silica adsorption properties of the peptide.  For a peptide that is 




favored in a crowded environment.  This would have not only reduce the peptide’s 
hydrodynamic radius but also increase its tendency to aggregate upon partial unfolding.  
As discussed in Section 1.3.2.2, both the folded and aggregated states are favored in a 
crowded environment.  In time, the solution sample in 10% HFIP gave a single minimum 
near 217 nm, indicating a beta fold and a local energetic minimum in the folding 
landscape (to be discussed later in Sections 3.4.2.1 and 3.5). 
Within the xerogel environment, the excluded volume effects driving the peptide 
to a more compact state and the helix-inducing effects of HFIP would compete, whereas 
in solution the excluded volume effects were absent.  This absence would indicate that 
the helical structure seen in solution is most likely not a compact stable intermediate but 
was instead a peptide with a large hydrodynamic radius consisting of helices and random 
coil secondary structures, with little stable tertiary structure.   
The probable beta structure observed for some samples in Figure 3-13 (bottom) 
was not expected.  Since Aβ should have been isolated in the pores of the silica matrix as 
a monomer, the peptide must have been able to form intramolecular β-strands not seen in 
solution.  Barrow and coworkers [101] found a similar spectrum in 25% TFE solution but 
demonstrated that the peptides had formed oligomers by centrifugation.  Here it appears 
that Aβ maked a structural transition from random coil to beta to α-helical in a 







3.3.2.2. Effects of KPhos Concentration 
The effects of KPhos concentration for solution/xerogel encapsulated Aβ in 

















































Figure 3-14. Xerogel encapsulated vs. soluble Aβ in KPhos at several concentrations.  
Top: solution at the indicated concentrations.  Bottom: xerogel encapsulated at the 
indicated concentrations.  Xerogel samples were too noisy below 207 nm to be 
interpreted.  All buffers were at pH 6.9, except the 1.00 M and 0.90 M samples that were 
at pH 6.8.  Both panels also contain the spectra of control samples incubated in H2O. 
 
 
xerogel spectra are reminiscent of some combination of random coil and α-helical 
structure, while the solution spectra are so weak that no conclusions may be drawn.  It 
can be seen that there was no notable difference in the encapsulated peptide’s spectra at 




significant increase in helical structure.  A similar trend was seen for encapsulated polyQ 
(Figure 3-8). 
 
3.3.2.3. pH Dependence in KPhos Buffers 
Figure 3-15 shows spectra for Aβ in 0.90 M KPhos solution and 1.00 M KPhos 
xerogel encapsulated peptides at pH 4.1, 6.8, and 11.4.  The xerogel spectra in Figure     
3-15 were taken after 19 h in solution and show increasing secondary structure with 
increasing pH, but, due to noise caused by high absorbance of the [PO43-] at the shorter 
wavelengths, the secondary structure was difficult to evaluate.  The solution spectra were 
taken after 1 h in solution, and, due to [PO43-] absorbance below 212 nm, the pH 11.4 
sample could not be evaluated.  At the lower pH values of 6.8 and 4.1, a single minimum 
in ellipticity was observed in each sample above 220 nm.  Because these minima did not 
occur at the same wavelength, it was difficult to conclude anything about the secondary 
structural content.  Aβ has an isoelectric point near pH 5.5 that falls just between two of 
the pH measurements [102].  Figure 3-16 shows these solution spectra at 19 h.  Both pH 
4.1 and 6.8 samples returned flat profiles indicating that aggregation might have 
occurred.  Upon visual inspection at this time point, the 3 ml centrifuge tubes contained 
white fuzz, reminiscent of loose cotton fibers, providing further evidence of aggregated 
peptide.  Because of this aggregation, comparison of the solution and xerogel spectra was 
complicated; diffraction has altered minima intensities, and aggregation rates may be a 

















































Figure 3-15. Comparison of pH dependence of soluble to xerogel encapsulated Aβ in 
























Figure 3-16. Soluble Aβ in 0.90 KPhos at the indicated pH for 19 h.  Samples at pH 11.4 
became extremely noisy below 212 nm so data was not taken.  The flat zero spectra of the 
pH 4.1 and 6.8 samples indicate that no significant amount of protein remains in the 




11.4 was stable over a 19 h period, which is consistent with previous findings [102] and 
indicated that the peptide remained soluble under basic conditions. 
Aβ in 45.0 mM (solution) and 50.0 mM (xerogel) KPhos at pH 4.5, 6.9, and 11.4 
can be seen in Figure 3-17.  In solution, the pH 4.5 sample shows a single minimum 
around 217 nm, which is a hallmark of beta structure, but difficult to interpret due to the 





















































Figure 3-17. Comparison of pH dependence of solution to xerogel encapsulated Aβ in 
45.0 mM and 50.0 mM KPhos solutions, respectively.  Xerogel samples became noisy 
below 205 nm.   
 
 
both returned random coil spectra with the pH 11.4 sample returning the strongest 




the sample at higher pH was found to be less likely to aggregate.  Similar to the 1.00 M 
KPhos samples, the xerogel-encapsulated samples appeared to be mostly random 
coil/helical with an enhanced intensity with increasing pH (Figure 3-17 bottom).   
 Figure 3-18 for 9.0 mM (solution) and 10.0 mM (xerogel) KPhos shows similar 
results as Figure 3-17 except that, in solution, the sample at pH 6.9 now had a single 
minimum near 217 nm and the pH 4.7 sample was random coil.  A complete loss of 
signal occured at pH 6.9 after 168 h, which may indicate that the spectrum in Figure 3-18 
was compromised by diffraction.  The soluble spectra were hard to interpret because of 
their weak signal intensity, which further suggests diffraction problems due to 
aggregation.  Xerogel samples at low KPhos concentrations again showed an increase in 
secondary structure with pH, as indicated by the minimum near 222 nm.  The pH 
dependence of these samples was only apparent in the pH 11.1 sample, whereas the 4.7 
and 6.9 samples returned almost identical spectra. 
 Below Figure 3-18, the Aβ peptide sequence is given with the residues that would 
be ionized under the specific conditions of this work: red (anion), and blue (cation).  The 
N- and C-terminals are given but because they cancel, they are neglected in the total 
charge calculation for all but the basic condition.  The residue number is indicated above 
each 10th residue.  Note that in acidic conditions at pH 4.1, glutamic acid (E) and aspartic 
acid (D) were near their pKa values where they are only half ionized.  This was the 
condition for the 1.0 M and 0.9 M samples, but not the others, and is indicated in the 
acidic sequence by underlining the residues.  The pKa values for each residue and the 




















































Figure 3-18. Comparison of pH dependence of solution to xerogel encapsulated Aβ in 
9.0 mM and 10.0 mM KPhos solution, respectively.  Xerogel samples became noisy 
below 205 nm.   
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Table 3-2. Aβ Side Chain pKa Values and  












Asp 3.9 3 0 --> -1 
Glu 4.3 3 0 --> -1 
His 6.0 3 +1 --> 0 
Tyr 10.1 1 0 --> -1 
Lys 10.5 2 +1 --> 0 
Arg 12.5 1 +1 --> 0 
Change in Charge indicates the change taking place as the  
pH is increased above the pKa value.  pKa values from [4]. 
 
 The change in overall charge may explain why the samples at the higher pH 
showed increased solubility.  The total charge of the peptide would create a repulsive 
effect, preventing aggregation.  In addition, the peptide itself would have felt an 
intramolecular net repulsion between residues 1 to 23, since all the charged residues exist 
within this region.  Therefore, any secondary structure formation should be driven by the 
high concentration of PO43-. 
 At neutral and acidic pH values, it can be seen that the positive and negative 
charges are interspersed along the peptide’s backbone, reducing any repulsive effect.  
This would have favored aggregation, as was seen in the 0.9 M sample, by allowing for 
more random intramolecular, and possibly intermolecular, electrostatic interactions.  In 
addition, at these pH values the number of uncharged residues was reduced, thereby 
reducing the hydrophobic driving force behind folding.  Therefore, it is highly probable 
that the diffraction-related spectrum was the result of large aggregated peptides, and the 




 Following encapsulation, all samples except the 1.00 M KPhos and all pH 11 
samples, showed mainly random coil character similar to the non-aggregated samples in 
solution, but with slightly more helical structure.  Neutral and acidic samples were 
essentially the same in all cases, with the basic samples returning stronger signals.  This 
similarity to the solution spectra could indicate that the peptide had not been adsorbed to 
the silica surface and that the structures of the monomeric peptides were similar in both 
cases.  Furthermore, since none of the samples had a net positive charge, attracting the 
peptide to the negatively charged SiO-, adsorption was not likely.  The increased helical 
structure can be explained by excluded volume effects, favoring a more collapsed fold.  
This increase in helical structure was most pronounced in the basic pH samples where 
folding was driven by the hydrophobic effect, and it may be that the hydrophobic regions 
were forming a tight coil. 
 
3.3.3. Comparison of PolyQ and Aβ Spectra 
 Solution and xerogel spectra for both polyQ and Αβ showed an increase in 
secondary structure as KPhos concentration was increased at near neutral pH, with the 
exception being that the 10.0 mM/9.0 mM  50.0 mM/45.0 mM transition was 
negligible in some cases (Figures 3-8 and 3-14).  This increase is in agreement with the 
Hofmeister Series and with the structure-stabilizing properties of the phosphate ion.  At 
the high pH used in these experiments, the phosphate ion would have largely been in the 
PO43- state, which is a strong kosmotrope that enhances peptide stability, while at low pH 




kosmotrope.  At high pH, both polyQ and Aβ had a net negative charge that would have 
caused a repulsive force, preventing intermolecular peptide aggregation (Section 3.3.2.3 
for Aβ).  Under the conditions of this work, polyglutamine with the flanking lysines and 
aspartates would have had no net charge until above pH 10.5 where it had a net negative 
charge at the N-terminus, due to the two aspartates.  Therefore, at high pH both peptides 
had a net negative charge, but while Aβ contained hydrophobic residues to drive folding, 
polyQ contained only hydrophilic residues at this pH [109, 110].  As discussed in Section 
3.3.2.3, Aβ took on more intermittent charge distributions and had more charged residues 
at the lower pH values that may have dominated the folding process.  Since these residues 
should have interacted more favorably with the solvent, tight packing of the residues, or 
the hydrophobic effect, would not have been the dominant driving force for folding.  On 
the contrary, polyQ’s termini became oppositely charged, favoring both intermolecular 
and intramolecular attraction.  Also, it was found by Sereda and coworkers [110] when 
studying protein binding as a function of the hydrophobicity of the environment that 
glutamine became less hydrophilic and more neutral as the pH was decreased.  This 
neutrality should have allowed polyQ to fold into a monomeric coil, which could explain 
the increased helical structure upon encapsulation, or to have formed small soluble 
oligomers in solution, which may have remained largely unstructured since the glutamine 
side chain was both bulky and neutral.  This bulkiness would have driven the coiling in 
the monomeric form due to the steric constraints of the alternating side chains that 





The difference in the amino acid content explains the difference in the two 
peptides’ structural dependence on KPhos concentration and pH.  Comparing each 
peptide only to itself, Aβ showed an increase in structure at high pH and an increased 
stability, while polyQ showed a decrease in structure.  In addition, in all cases, save the 
Aβ 45/50 mM KPhos pH 4.5 spectra, there was an increase in secondary structure in 
xerogel samples.  As previously stated, the glass added two factors that may cause this 
increase: excluded volume effects and the F3-propyl glass modifier.  These effects act 
independently of one another and so should be thermodynamically addressable by 
separate routes, meaning the use of different solutes or surface modifiers could be used to 
control these effects independently.  As an example, overlapping effects are apparent at 
the higher HFIP concentrations where the influence of the F3-propyl modifier became 
less obvious as compared to solution.  
 
3.4. Stability of Solubilized Peptides in Solutions vs. Time  
To check the solubilized peptides’ resistance to aggregation in the various 
solvents, spectra were taken over a period of 504 h, or 21 days.  Signal intensities at 205 
nm, 217 nm, and 222 nm were plotted separately as a function of time.  Plotting 
ellipticity at these wavelengths allows secondary structure to be evaluated, providing 
insight into which structures were resistant or most prone to aggregate: 205 nm is 
indicative of random structure, 217 nm of beta, and 222 nm of helical.  A complete loss 





3.4.1. Soluble PolyQ Peptide 
3.4.1.1. HFIP Solutions 
All three wavelengths at each HFIP concentration can be seen for polyQ in Figure 
3-19.  The complete profile (full spectra) for these samples at 24 h can be seen in Figure 
3-7 (top), and the 0% spectrum can be seen in Figure 4-6.  Figure 3-20 (top) gives the full 
spectra for the 0% HFIP sample over a period of 1008 h, which was the only solution that 
returned a positive 205 nm ellipticity at 504 h.  The bottom panel of Figure 3-20 gives the 
1% sample over a period of 504 h.  The only difference between the 1% and 5% samples 
in time was that the 5% had a more intense signal.  The spectra taken at 1 h indicate 
random coil structures and all slowly lost intensity at 205 nm over time.  The 0% spectra 
slowly folded to a curve indicating beta structure at 504 h, and it can be seen that there 
was a loss of intensity at 1008 h, indicating aggregation.    
An isodichroic point can be seen in Figure 3-20, which indicates a two state 
folding transition between random coil and possibly beta sheet secondary structures.  
This isodichroic point suggests that both the 1% and 5% samples may have followed the 
same trend, though analysis at 1008 h returned a flat-zero spectrum for both low percents 
HFIP.  It is possible that this weak beta spectrum was that of small soluble pre-fibril 
aggregates, consistent with the fact that the 504 and 1008 h spectra appear to be centered 
near 217 nm.  
Comparing all three wavelengths, it can be seen that 10% and 25% HFIP 
solutions returned ellipticity values that parallel each other in terms of signal loss at each 




with theory since these samples had more helical structure than the others (seen in Figure 
3-7).  Therefore, polyQ became more aggregation resistant with increasing helical 







































































































































Figure 3-20. Structural stability of soluble polyQ in water and 1% HFIP.  Top (water) 
and bottom (HFIP).  Note the isodichroic point near 213 nm indicating a two-state 
folding transition between random coil and a possible beta sheet or aggregate structure.   
 
 
3.4.1.2. Effects of KPhos Concentration 
The time dependence for the structures analyzed at 205 nm for soluble polyQ in 
0.90 M, 45.0 mM, and 9.0 mM KPhos can be seen in Figure 4-21 (Figure 3-8 for full 
spectra after 24 h in solution).  All solutions gave random coil spectra with some helical 
content and retained their general shape as their signals weakened in time.  All solutions 




gave a weak, positive, and noisy signal at the 504 h data point, which was probably due 
to contamination; at 336 h very little of this sample was left, so the contents of the quartz 
cuvette was returned to the 3 ml centrifuge tube after the spectrum was taken.  The 
sample contained a visible precipitant at 504 h that was similar to the other two samples 
and resembled loose cotton fibers. 
The HFIP stability support the statement in Section 3.4.1.1 that polyQ became 
more aggregation resistant with increasing helical structure.  Furthermore, this statement 
is in agreement with current theory on polyQ repeat diseases.  The length of the repeat is 
associated with the extent of destabilization, or random structure, in the affected peptide 
and with the rate of aggregation.  Here, and in the previous section, it has been shown 
that the more random the structure, the higher the rate of signal loss due to aggregation.  
Non-pathogenic huntingtin protein is an ordered peptide.  In the pathogenic version, as 
the number of glutamine repeats increases, the protein becomes more destabilized and 
























Figure 3-21. Stability of soluble polyQ in 0.90 M pH 6.8, 45.0 mM pH 6.9, and 9.0 mM 
pH 6.9 KPhos solutions, 205 nm signal intensity.  Spectra were taken at 1, 19, 168, 240, 




3.4.1.3. pH Dependence in KPhos Buffers 
The pH dependence for polyQ in 0.90 M KPhos can be seen in Figure 3-22.  The 



































































Figure 3-22. Stability of soluble polyQ in 0.90 M KPhos at pH 4.1, 6.8 and 11.4.  Due to 





seen in Figure 3-9 (top).  Signal loss occured fastest at pH 6.8 indicating that, of the 
samples, polyQ was most prone to aggregation at this pH.  At 168 h, the samples at 
pH 4.1 contained aggregates upon visual inspection, but still had a weak minimum below 
212 nm at 1008 h.  A single minimum around 222 nm was seen in the pH 11.4 sample, 
but was too noisy below 212 nm to determine the structure.  The signal slowly flattened 
to zero at 1008 h and upon visual inspection contained aggregates resembling a small 
amount of cotton fibers floating in the 3 ml tube.  This pH extreme would have given the 
peptide a net negative charge due to the two aspartates, which might have created a 
repulsive force that slowed aggregation.  At pH 4.1, as discussed in Section 3.3.3, the 
phosphate ion would have largely been in the H2PO41- state, which is a weaker 
kosmotrope than HPO42- or PO43-.  Previous studies, under different conditions as 
discussed in Section 1.6.1, had determined that the monomer had a random coil structure 
[93], and since there was a steady loss of signal at all wavelengths with no isodichroic 
point, interpretation under this condition was difficult. 
 Figure 3-23 shows similar data for polyQ in 45.0 mM KPhos.  The spectra seen in 
Figure 3-10 (top) summarize the 24 h time point spectra for this KPhos concentration.  
All three pH values gave the same random coil spectra throughout the experiment 
without changing general shape, but flattening to zero in time.  At this concentration the 
sample at pH 11.4 was the most resistant to aggregation, as seen by the intensity at 210 
nm at 1008 h.  At the lower concentration of 9.0 mM, the data again showed that the 
higher pH sample was the most aggregation resistant (Figure 3-24).  As with the 45 mM 




throughout the experiment and slowly flattened to baseline.  A slight difference was that 
the pH 4.5 sample flattened to zero at the last time point at this concentration, whereas it 































































































































































interpreted at 205 nm, in 45.0 mM KPhos it gave the most stable signal intensity.  
Otherwise, these two samples, acidic and basic, closely paralleled each other’s stability at 
217 nm and 222 nm.  As stated before, at high pH the [PO43-] was prevalent, and it is 
expected to be a powerful kosmotrope that tends to increase peptide structural stability.  
This, with the fact that the peptide would have had a net repulsive charge, explains the 
increased time stability of polyQ at all KPhos concentrations when at high pH.  What 
cannot be explained by this data was the increased stability in time of the acidic samples 
over the neutral pH, especially since at neutral pH the [H2PO41-] should have shifted 
towards the more kosmotropic [HPO42-]. 
 
3.4.2. Soluble Aβ Peptide 
3.4.2.1. HFIP Solutions 
 Figure 3-25 shows the time dependent data for Aβ in HFIP solutions over a period 
of 3 weeks.  The 24 h full-wavelength spectra can be seen in Figure 3-13 (top).  All 
spectra retained their general shape throughout the experiment except for the 10% HFIP 
sample.  The 10% HFIP sample had no sign of aggregation upon visual inspection at 
504 h but instead depicted a change in secondary structure from a helical spectrum to a 
stable beta spectrum.  The 10% HFIP slope began with random coil, 210 nm and 222 nm 
being the stronger signals, but folded to a typical beta spectrum with the 217 nm signal 
being the strongest.  The full spectra for 1 and 504 h can be seen in Figure 3-30 in 
Section 3.5 where they are discussed further.  After the formation of this beta spectrum 





















































































































secondary structure compared to the 1% sample, as indicated by the more intense 205 nm 
signal.  This spectrum is typical for random coil and was the only sample to flatten to 
zero in the time of the experiment.  The sudden loss of signal may be due to aggregation 
or proteolytic degradation.  Except for the 10% HFIP sample, all other samples were 
stable with time. 
 
3.4.2.2. Effects of KPhos Concentration 
The Aβ peptide quickly aggregated out of solution in 0.90 M, 45.0 mM, and 9.0 
mM KPhos solution at neutral pH.  The ellipticity values at 205 nm, 217 nm, and 222 nm 
can be found in Figures 3-27 to 3-29 as a function of time.  The 0.90 M signal reached 
the baseline in less than 19 h at pH 4.1 and 6.8 (Figure 3-27).  The 45.0 mM and 9.0 mM 
samples gave flat-zero spectra in less than 7 days at similar pH values (Figures 3-28 and 




approximately 2 h after beginning the resuspension, can be seen in Figure 3-14.  No 
changes in the general shapes of the spectra were observed. 
 
3.4.2.3. pH Dependence in KPhos Buffers 
Data for the pH dependence of soluble Aβ at each phosphate concentration is 
summarized in Figures 3-27, 3-28, and 3-29.  The full spectra for the 0.90 M sample at 
1 h can be seen in Figure 3-15, and the full spectra for the 24 h time point in 45.0 mM 
and 9.0 mM KPhos can be seen in Figures 3-17 and 3-18.  In all cases, the samples near 
pH 4 and pH 7 aggregated out of solution well before the basic sample near pH 11.   
The 0.90 M samples at pH 4.1 and 6.8 gave a single weak minimum above 
220 nm with a positive signal below 210 nm at 1 h and contained aggregation upon visual 
inspection at 19 h.  This rapid aggregation supports the previous proposal that these 
spectra are affected by diffraction of larger aggregates still in solution.  The data here 
suggests that these red shifted spectra originate from samples containing these larger 
aggregates that are still forming.  At the same concentration, the pH 11.4 sample gave a 
week minimum near 222 nm but was too noisy below 212 nm to gain any structural 
information.  The shape of the discernible region of the spectrum did not change in the 
time period of the experiment.  The stability of the sample at pH 11.4 indicated that it 
was least prone to aggregation, whereas the other two that started with a single weak 














































































Figure 3-27. Stability of soluble Aβ in 0.90 M KPhos at pH 4.1, 6.8, and 11.4.  The 





































































































































































In 45.0 mM KPhos, all Aβ samples gave similar random coil spectra at 1 h.  At 
19 h, the peptide at pH 4.5 gave a single weak minimum around 217 nm and at 168 h 
took on some random structure indicated by a loss of the 217 nm intensity signal and a 
completely negative signal below 236 nm.  The 217 nm signal continued to weaken and 
eventually became positive after 240 h with a negative signal at 205 h.  This change in 
spectra suggested that the peptide unfolded from a beta fold to a highly random coil fold 
before it aggregated out of solution.  At 240 h, the pH 6.9 sample gave a flat-zero 
spectrum indicating aggregation.  The two samples at the lower pH values developed a 
white film on the bottom of their centrifuge tube, most likely due to aggregation.  The 
sample at pH 11.4 again proved to be most aggregation resistant, and this property was 
most likely due to a negative repulsive charge on the peptide at this pH that dominated 
over the hydrophobic driving force of peptide aggregation. 
A random coil spectrum was observed for all samples in 9.0 mM KPhos at 1 h, 
and again the two samples at lower pH values quickly aggregated out of solution.  This 
profile was retained throughout the experiment by all samples.  Aggregation was 
observed in the pH 4.7 sample at 168 h.  Again, the peptide sample at pH 11.7 showed 
the most resistance to aggregation.  A conclusion drawn from all these spectra, and in 
agreement with theory, was that the peptide must be partially unfolded or adopt a random 
coil structure before aggregation.  All samples with stable secondary structure appeared 






3.5. Soluble vs. Aggregated Peptide Spectra 
In solution, solubilized Aβ initially yielded three different spectra depending on 
the solvent: random coil/molten globule, beta sheet, and an anomalous profile that 
yielded a minimum anywhere between 220 nm and 230 nm, likely due to diffraction.  It 
was this third type of spectrum that is proposed to be the result of actively aggregating 
peptides and, therefore, that of a species whose solubility was decreasing.  Spectra with 
red shifted minima tended to have spectra that flattened to zero faster than any other, 
indicating aggregation.  The other two structure classifications showed increased stability 
with increasing secondary structure that can be measured by the 217 nm and 222 nm 
signal intensities.  The increased strength of these signals, relative to the rest of the 
spectrum, returned increasingly stable spectra in time.  Above, it was shown that Aβ in 
10% HFIP solution initially gave a random coil spectrum that shifted to a species that 
yielded a stable beta sheet spectrum.  Figure 3-30 shows a comparison of these two types 
of soluble (top) and aggregated (bottom) species.  The spectra of aggregated Aβ species 
were taken from 0.90 M KPhos samples at pH 4.1 and 6.8.  The samples were vortexed 
for 30 s to resuspend the fibers, and the spectra were immediately taken.  Notice the 
similarity between these resuspended aggregates and the spectra shown in Figure 3-15 
(top) for the same peptide sample before precipitation. 
Looking at the stable/soluble spectra in Figure 3-30, it can be seen at 1 h (blue) 
that the 10% solution gave a helical structure profile but evolved into a stable beta 
structure (black) at 504 h.  Once this beta structure formed with the characteristic 


























5% at 1 h
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Figure 3-30. Analysis of soluble vs. aggregated species in solution.  Top: Aβ in 5% and 
10% HFIP solutions at 1 and 504 h.  Bottom: Vortexed aggregates of Aβ in 0.90 M 
KPhos solution.  Samples were vortexed for at least 30 s to resuspend the amyloid fibers, 
and the spectra were taken immediately. 
 
 
Figure 3-25, 336 – 504 h).  The sample at 5% HFIP (green and red) returned spectra that 
were both negative at 200 nm, which is characteristic of random coil structure.  The inset 
in Figure 3-13 shows the spectrum for this sample after 1 day in solution.  In this 
spectrum, there is a minimum near 210 nm that may indicate the peptide had begun to 




aggregated spectra have a single minimum between 220 nm and 230 nm.  Therefore, if a 
red shift in minima is observed in the other more typical spectra, this may indicate that 
aggregation is occurring. 
 
3.6. Structural Changes of Encapsulated Peptides vs. Time 
3.6.1. Encapsulated PolyQ 
Encapsulated polyQ showed little change in structure as a function of time when 
it was stored in the same solution throughout the experiments.  In the absence of leaching 
during solvent exchange, the spectra were relatively stable, and, because the peptide was 
only 15 glutamine residues, 19 amino acids in total, there was little driving force for the 
peptide to form any stable structure.  The one observed change was in a partially prepared 
xerogel glass that was not allowed to shrink to completion; the final size was 
approximately 75% the total original volume.  Over a period of 3 days, the sample 
changed from a helical spectrum to a single minimum near 220 nm (Figure 3-31).  On the 
third day the sample had become visibly foggy, perhaps indicating a light diffraction 
problem.  A comparison of the spectrum 3 days after to the solution spectrum in H2O 
after 1008 h (inset) showed almost identical results.  It’s unlikely that large aggregates 
formed in the xerogel because: (1) even small aggregates would not easily diffuse 
through the xerogel matrix to form larger ones, and (2) thermodynamically, the peptides 
would not be driven to a central pore to form a large aggregate.  Therefore, the changing 
spectra in Figure 3-31 arise from some other diffraction-related phenomenon, such as 




effects should favor a more compact state, and therefore, a tighter packing of the 



























Figure 3-31. Aggregation of glass encapsulated polyQ.  The partially dried glass was not 
allowed to shrink to completion which may have allowed the peptide to leach through the 
matrix and to form oligomers.  The sample was kept at 25°C in 1.00 M KPhos.  The glass 
was clear on the first day and slowly became foggy.  Notice the evolution of a single 
minimum close to 220 nm.  This is likely red shifted due to diffraction.  Inset:  Soluble 
polyQ in H2O after 1008 h (Figure 3-20 top). 
 
 
3.6.2. Encapsulated Aβ 
 Figure 3-32 shows spectra for the 25% HFIP sample at 1, 50 and 54 days.  Here 
the sample initially gave a spectrum that appeared to contain both helical and beta 





































Figure 3-32. Xerogel encapsulated Aβ in 25% HFIP in H2O (v/v) at 1, 50, and 54 days.  
At day 1 (blue) the spectra is that of a mixed beta and helical structure.  On day 50 (red) 
the spectra is that of random coil indicating that the much of the secondary structure has 





222 nm.  When the peptide unfolded at day 50, it retained some structure as seen by the 
signal near 217 nm.  At day 54 a single minimum was observed near 217 nm that may 
indicate a significant amount of beta structure.  This was also observed in the 10% HFIP 
solution, discussed in Section 3.5, and may indicate a semi-stable folding intermediate.  
Even if these results were due to evaporation of the HFIP, the negative signal at 200 nm 
in the day 50 spectrum was not observed at a HFIP concentration between those 
concentrations that returned similar spectra to the 1 and 54 days spectra (Figure 3-13).  
Since the HFIP concentration could not have increased between day 50 and 54 this data 






3.7. Thermal Stability 
3.7.1. Thermal Stability of Soluble Peptides 
Temperature did not induce aggregation in any of the solution experiments, and 
all samples showed complete reversibility.  Figure 3-33 shows the 222 nm signal for 
polyQ in H2O upon heating.  The change in ellipticity was negligible and most likely 
represented noise in the system.  Without aggregation, the steady signal intensity was to 
be expected in a sample with random structure, such as this sample.  Samples that started 
with increased secondary structure should have shown a change in signal intensity as a 
function of temperature, as was the case in Figure 3-34 for soluble polyQ in 25% HFIP.  
In the top panel, the 222 nm signal for heating and cooling can be seen, and in the bottom 





























Figure 3-33. Thermal stability of polyQ in H2O by tracking ellipticity at 222 nm.  The 
background has not been subtracted.  A temperature step of 5°C was used with an 
equilibration time of 30 s and 1 s averaging time.  Data shown is for heating only.  The 
initial solution structure is that seen in Figure 3-6.  Since the structure was already 
































































Figure 3-34. Thermal stability of soluble polyQ in 25% HFIP in H2O (v/v).  Top: 222 nm 
signal intensity as a function of temperature.  Bottom: spectra at 25°C before heating 
(blue), at 75°C before cooling (red), and at 25°C after cooling (green).  The background 
has not been subtracted for 222 nm signal intensity curves (top), but has been for the 
spectra (bottom).  A temperature step of 5°C was used with an equilibration time of 15 s 





are displayed.  Notice that, noise aside, the spectra were completely reversible and there 

































































Figure 3-35. Thermal stability of soluble Aβ in H2O and 25% HFIP 222 nm signal 
intensities.  Top (H2O) and bottom (HFIP).  The background has not been subtracted.  A 
temperature step of 5°C was used with an equilibration time of 30 s and 1 s averaging 
time.  Data for the sample in water (top) is for heating only.  The 25% HFIP sample was 
held at 75°C for 5 min between heating and cooling.  The initial solution structures are 
those seen in Figure 3-12 and 3-13.  Since the sample’s structure in water was already 
random coil, heating had little effect, as indicated by the relatively flat line.  The 25% 




conditions as those for polyQ that returned very similar results (Figure 3-12 and 3-13 for 




These results were to be expected in the random coil spectra since the peptide was 
already mostly disordered.  Samples showing secondary structure were expected to 
aggregate upon cooling since they would be partially disordered along this path.  This 
lack of aggregation would indicate that the helical random coil structure with strong 
222 nm and 205 nm signals were largely molten globule with some helical structure.  A 
similar experiment was not performed on a sample showing beta character, but it would 
be interesting to see if the results were similar.  It is possible the peptide would aggregate 
out of solution upon partial unfolding (slow heating) when the hydrophobic beta core is 
exposed, should the HFIP not help to stabilize the structure.  Upon cooling after 
unfolding, the peptide may return a molten globule spectrum. 
 
3.7.2. Thermal Stability of Encapsulated Peptides 
In general, all structural changes that took place during thermal experiments were 
reversible.  A slight loss of signal sometimes occurred that was most likely due to 
leaching of the peptides through the xerogel matrix at elevated temperatures.  Leaching at 
room temperature was shown in Figures 3-4 and 3-5, where it was demonstrated that 
leaching was reduced in xerogels relative to wet-aged glasses.  Figure 3-36 summarizes 
the data for polyQ in H2O at temperatures both above and below 25°C.  In both cases, 
when the temperature was returned to 25°C, the original spectrum was largely recovered. 
In samples that showed highly disordered spectra, as that shown in Figure 3-37 
for encapsulated Aβ in H2O, the 222 nm value did not change as a function of 
































Figure 3-36. Xerogel encapsulated polyQ in H2O gives a reversible secondary structure 
at high and low temperatures.  The temperature was varied as indicated by the arrows 
from left to right, indicated by the key, beginning at the top and moving successively 
downward.  Each spectra was taken when the ellipticity at 222 nm stabilized, 
approximately 2 to 5 min after the indicated temperature was reached. 
 
 
of an irreversibly adsorbed protein.  Only one other structure demonstrated similar 
thermal stability after encapsulation, the beta structure of Aβ peptide after 2 months.  
Figures 3-38 and 3-39 show these beta spectra at several temperatures and demonstrate 
the stability of the structure.  Figure 3-38 shows the spectra for the sample in 25% HFIP 
after 54 days at the indicated temperatures.  The spectral shape indicate that there was 
probably some random coil structure because of the spread of the signal between 210 nm 


























































Figure 3-37. Xerogel encapsulated Aβ in H2O as a function of temperature.  Top:  The 
222 nm signal intensity as a function of temperature.  Bottom:  Spectra at 25°C before 
(blue) and after (red) heating and cooling.  The sample was stored in a 3 ml cuvet at 25°C 




the intensities of this region.  Unfortunately, the experiment was interrupted by a sudden 
drop in the pressure of the gas used to cool the lamp in the CD instrument, and a larger 
range of temperatures could not be explored.  Figure 3-39 shows the sample in water after 
































Figure 3-38. A small variation in temperature has little effect on Aβ’s secondary 
structure in 25% HFIP.  The temperatures were varied as indicated by the key from top to 
bottom.  The spectra were taken when the ellipticity at 222 nm stabilized, approximately 

































Figure 3-39. Thermally stable encapsulated Aβ in pure water for 54 days.  The shape is 
similar to the reversible alcohol induced beta Xerogel spectrum.  Once this data was 
collected the sample was placed in 50% HFIP for 24 h and the spectrum was taken.  The 
217 nm signal intensified and flattened out around 210 – 220 nm, indicating the presence 












this structure: (1) the structure was a semi-stable intermediate, (2) the peptide had leached 
through the glass and aggregated, or (3) it had become irreversibly adsorbed to the glass.  
After the data was taken the sample was transferred to 25% HFIP and allowed to 
equilibrate at room temperature over night.  The inset of Figure 3-39 compares the 25°C 
spectrum of the main panel to the spectrum taken in 25% HFIP at 25°C.  The increase in 
intensity was most likely due to unstructured regions of the peptide taking on helical 
structure. 
 
3.8. Effects of Solvent Exchange on Encapsulated Peptide Secondary Structure 
 To test further the folding landscape of the two peptides in this study, and to 
search for stable intermediate states, xerogel samples were swapped between the different 
solvents used to characterize these peptides.  If the spectra showed an irreversible change 
or the existence of multiple folds over a narrow range of solvent concentrations, then 
intermediates may possibly be identified.  In addition, if certain spectra of soluble 
peptides not yet seen in xerogel samples were produced, then the thermodynamic effects 
of the xerogel matrix may be further characterized.  And if the conditions corresponding 
to these spectra are known to lead to aggregation in solution then, not only do we learn 
about the folding path to these states and the stabilizing effects of excluded volume, but 
we also learn what solvent conditions may induce these states.  In addition, defining such 
conditions would allow one to begin the investigation of how to prevent the formation of 




 During solvent exchange, because there was already solvent within the xerogel, 
some of the previous solvent would have been carried over to the new solvent.  A 
generous estimation of the xerogel’s volume that was solvent would be 80%.  This 
estimation corresponds to a volume of just 0.04 ml for a typical glass sample.  Each 
sample was incubated in 3.00 ml of the new solvent before the spectra were taken.  Thus, 
the percent of the old solvent volume in the new solvent was about 1.3%.  An example of 
the approximate change in concentration when moving a sample from 35% to 5% HFIP 
would be 
((3.00 ml x 5.00%) + (0.04  ml x 35.0%))/3.04 ml = 5.39% HFIP (v/v). 
Likewise, the change from water to 5% HFIP would result in an effective concentration 
of 4.93% HFIP, with a difference of 0.46% HFIP between the two re-equilibrated 
examples above.  Where appropriate, these changes will be discussed in further detail. 
 
3.8.1. PolyQ 
3.8.1.1. Exchanges between HFIP and Water 
An increase in helical secondary structure was seen with increasing HFIP 
concentration for encapsulated polyQ.  To check the reversibility of these structures, 
xerogel samples were incubated in 1%, 5%, 10%, 25%, 35%, and 42% HFIP in H2O (v/v) 
for 24 h, and the CD spectra were taken.  After rinsing with H2O, the samples where 
allowed to equilibrate for 1 h and then replaced with fresh H2O.  At hour 48, 24 h after 




return each sample to its original HFIP concentration.  Figure 3-40 shows these three 
spectra for each HFIP concentration. 
All experiments except the 1% and 10% samples showed complete reversibility.  
The 1% sample was uninteresting due to the fact there was no difference between the 
original spectrum and the H2O spectrum.  This general reversibility was an indication that 
the xerogel samples did not form any stable irreversible structures and that the peptide 
did not transition through a highly unstructured state.  The 10% sample was the only one 
that showed a modest failure to completely recover its original CD profile.  Since the 
experiment was not repeated, it is possible that the glass was not made uniformly and that 
the 72 h spectrum was not taken from the same region of the glass.   
To further investigate the influence of these solvents on the secondary structure of 
polyQ, the 48 h spectra of the samples in Figure 3-40, all in H2O, were compared, as seen 
in Figure 3-41.  To provide a basis of comparison, the spectrum of a control sample that 
had only been equilibrated in H2O has been added.  This spectrum was obtained at the 
initial 24 h time point, and the sample was cut from the same glass.  Thus, the significant 
differences between the control and all other sample were: (1) the control had only been 
in solution for 24 h, whereas the other samples were 48 h old, (2) the control had not 
gone through a solvent exchange, and (3) there was no residual concentration of HFIP in 
the control as a result of a solvent exchange.  Although difficult to discern in Figure 3-41, 
there was an increase in ellipticity with increasing initial HFIP concentration, and all 
except the sample that came from 42% HFIP were slightly less intense than that of the 


















































































































































Figure 3-40. Solvent exchange effects on encapsulated polyQ from the indicated %HFIP 
(24 h) to water (48 h) and back (72 h).  After the spectra were taken, the sample was 
allowed to equilibrate for 1 h in the new solvent at which time the solvent was drained 
and replaced with a fresh sample of the new solvent.  This was done to reduce the amount 



































Figure 3-41. Comparison of polyQ samples in 0% HFIP for 24 h after initially incubating 
in the indicated %HFIP for 24 h.  The same as those shown in Figure      3-40.  After the 
spectra were taken, the sample was allowed to equilibrate for 1 h in the new solvent at 
which time the solvent was drained and replaced with a fresh sample of the new solvent.  
This was done to reduce the amount of the previous solvent carried over in the xerogel 
matrix.  Inset:  Comparison of the initial 24 h spectra of the 0% and 1% samples.  Spectra 




HFIP samples.  The inset shows the 24 h spectra for the 0% and 1% HFIP samples.  It 
can be seen that the 1% sample had a decreased ellipticity which may indicate that very 
low concentrations of HFIP actually reduced secondary structure, or that, when the 
samples were initially placed in their respective HFIP concentrations, some amount of 
leaching had occurred since the samples were rehydrated with water after shrinking of the 
glass sample had ceased.  What is more notable is the similarity of all the spectra when 
this initial difference in the samples in 0% and 1% HFIP is taken into account and when 









exchange are accounted for.  The data indicated complete reversibility under the 
conditions of the experiment. 
 
3.8.1.2. Exchanges between KPhos and Water 
The effects of KPhos on polyQ’s secondary structure were not only dependent on 
concentration but also on pH.  Therefore, the three concentrations used previously at each 
of the three pH values were used in solvent exchange experiments, and a protocol 
identical to that described in the previous section was employed.  Figure 3-8 shows that, 
in 1.00 M KPhos at pH 6.8, there was an increase in ellipticity and that the spectra 
retained the same general shape.  Additionally, Figure 3-9 shows the pH dependence with 
pH 6.8 giving the strongest signal, pH 4.1 giving the weakest signal but with the same 
general shape, and pH 11.4 giving the most random structure with the signal near 207 nm 
being much more intense relative to that at 222 nm.  Figure 3-42 shows the spectra for the 
solvent exchange between these samples and water.  At an initial pH of 4.1, there was a 
small reduction in signal intensity when the spectrum was reanalyzed in water.  Upon 
return to the original solvent, the sample recovered its original intensity with a modest 
increase at 222 nm.  The source of this increase is unknown. 
In the sample at pH 6.8, there was a significant loss in signal intensity at 48 h 
when the spectrum was taken in water.  This extent of random coil shape was not seen in 
spectra of equivalent samples in water with no prior solvent incubation (Figure 3-8), but 
was similar to the spectrum obtained in 10.0 mM KPhos at the same pH.  This similarity 


















































































Figure 3-42. Solvent exchange effect on encapsulated polyQ from 1.00 M KPhos at pH 







KPhos was present in the 48 h spectrum.  Because this was a random coil structure, 
which was prone to leaching, and because the same general shape of the 24 h spectrum 
was regained at 72 h, just less intense, leaching must have been a factor during the 
experiment. 
A similar result was obtained in the pH 11.4 experiment at 24 and 48 h, except 
both spectra were more random in character as compared to the pH 6.8 experiment.  The 
72 h spectrum became too noisy below 210 nm to interpret, but the 222 nm signal was 
greatly reduced as compared to the 24 h spectrum.  Since the two previous spectra had 
increased random character, it was likely that leaching was much more of a factor than 
for the sample at pH 6.8.  Here the 48 h spectrum in water indicated a slightly more 
random structure than that of the 10.0 mM pH 11.1 sample seen in Figure 3-11, but the 
50.0 mM pH 11.4, seen in Figure 3-10, was more random in structure than the 10.0 mM 
sample.  Therefore, the spectrum at 48 h may have been of a low concentration of KPhos, 
near 10.0 mM, but at a higher pH, increasing its random coil structure.    
Both Figures 3-43 and 3-43 give results similar to one another and show signs of 
leaching, as observed in 1.00 M KPhos.  The effects of leaching were reduced in Figure    
3-44, which was to be expected since 10.0 mM KPhos is less concentrated than the 
50.0 mM used in Figure 3-43.  The changes in the spectra at the lower and neutral pH 
values in both of these figures, across the individual experiments, were negligible, but 
gave similar results as Figures 3-10 and 3-11 where the lower pH values were more 
helical than the neutral.  Figure 3-8 shows that the spectrum of the control sample in 













































































Figure 3-43. Solvent exchange effect on encapsulated polyQ from 50.0 mM KPhos at pH 













































































Figure 3-44. Solvent exchange effect on encapsulated polyQ from 10.0 mM KPhos at pH 







3-43 and 3-44 did not recover this structure, some rearrangement must have taken place 
in the original solution that was not energetically forbidden in water.  The concentration 
of KPhos in these samples at 48 h must have been miniscule.  The higher pH samples 
provide support for this last statement.  Both showed signs of leaching, and this leaching 
could only be driven by solvent exchange.  Each successive solvent exchange lowered the 
intensity of the spectra with little effect on the spectral shape.  At these lower 
concentrations of 10.0 mM and 50.0 mM any residual buffer carried over would result in 
a negligible concentration in the spectra at 48 h after the solvent had equilibrated. 
 Figure 3-45 shows the results from the reverse experiment where the sample was 
incubated first in water and changed to 50.0 mM KPhos at pH 11.4, and then back, using 























Figure 3-45. Solvent exchange effect on encapsulated polyQ from H2O to 50.0 mM 




reduction in intensity, indicating leaching, and that the 48 h spectrum shows a loss of 




difference between the two experiments provided further support that leaching was a 
factor for KPhos buffers of high pH.  Because both the peptide and the silica surface of 
the glass would be negatively charged at high pH, enhanced leaching may be due to 
charge repulsion. 
 
3.8.2. Solvent Exchange Studies with Aβ Peptide 
The experiments in section 3.8.1 for polyQ were simultaneously performed in an 
identical manner with Aβ peptide.  This includes peptide solubilization, glass preparation, 
and choice of all solutions.  Therefore, the only significant difference between the 
experiments was the peptide. 
 
3.8.2.1. Exchanges between HFIP and Water 
The results from Aβ peptide xerogel samples exchanged between HFIP solutions 
and H2O are shown in Figure 3-46 below.  Figure 3-13 showed that after 24 h of 
incubatiing there was an increase in ellipticity with increasing HFIP concentration, 
starting with a random coil spectrum and showing a significant amount of helical 
structure at the higher HFIP concentrations.  As in Figure 3-13, there was noise at the 
shorter wavelengths in Figure 3-46 making the spectra difficult to interpret.  Each set of 
spectra demonstrates the ability to take on the same random coil profile in water upon 
solvent exchange (Figure 3-47 top).  Upon return to the original solvent, the 10% sample 
showed a loss in ellipticity intensity that may indicate a slight loss of structure as 


















































































































































Figure 3-46. Solvent exchange effect on encapsulated Aβ from the indicated %HFIP 
(24 h) to water (48 h) and back (72 h).   
 
 
concentrations of 25%, 35%, and 42% all returned the same spectra, in the discernible 
region, upon return to their original solution (Figure 3-47 bottom).  These spectra appear 























































Figure 3-47. Comparison of Aβ samples at 48 (top) and 72 (bottom) hours during solvent 
exchange between HFIP and water for the indicated concentrations.  The same as those 




nm and 220 nm.  The fact that the ellipticity did not increase with increasing HFIP 
concentration above 25%, as seen at the first time point, may indicate the formation of 
some semi-stable secondary structure.  In addition, these spectra overlap with the original 
spectrum for the sample in 25% HFIP that was capable of unfolding to the same endpoint 




Figure 3-25 shows that just a slight increase in secondary structure decreased the 
rate of aggregation.  The reversibility of the conformational states shown in Figure 3-46 
is further demonstrated in Figure 3-47.  Here it is seen that, no matter the initial HFIP 
concentration, all samples adopt the same conformation in water at 48 h.  This is similar 
to the spectrum of the 0% HFIP sample in Figure 4-25 that precipitated out of solution 
(Figure 3-12).  Since Aβ is believed to aggregate from a disordered state, this finding is 
significant because it demonstrates that the peptide’s secondary structure is highly 
sensitive to its environment.   
 
3.8.2.2. Exchanges between KPhos and Water 
In Figure 3-14 it was shown that encapsulated Aβ increased in ellipticity with increasing 
KPhos concentration.  Both 10.0 mM and 50.0 mM KPhos showed similar random 
structure as observed in water and were just slightly increased in intensity, whereas the 
1.00 M spectrum appears to be more helical and was the strongest signal.  The 
corresponding time stability data in Figures 3-27 to 3-29 show that Aβ quickly 
aggregated out of solution at the two lower KPhos concentrations.  It was also shown in 
these experiments that the samples at lower pH aggregated out of solution at 
approximately the same time.  Only the samples at the higher pH values showed any 
amount of time stability in solution, and this stability increased with increasing phosphate 
concentration.  It has been mentioned that the peptides at the higher pH values have a net 
negative charge causing a repulsive force, which would have prevented aggregation.  In 




48 to 3-50 below give the spectra for solvent swap experiments between KPhos, to water, 









































































Figure 3-48. Solvent exchange effect on encapsulated Aβ from 1.00 M KPhos at pH 4.1 

















































































Figure 3-49. Solvent exchange effect on encapsulated Aβ from 50.0 mM KPhos at pH 














































































Figure 3-50. Solvent exchange effect on encapsulated Aβ from 10.0 mM KPhos at 






changes in the spectra were observed. 
 One experiment that returned interesting data is seen in Figure 3-48 (bottom) for 
the 1.0 M KPhos sample at pH 11.4.  A major problem with this pH at this concentration 
was that the CD signal became too noisy at the shorter wavelengths and the spectra could 
not be interpreted.  After the sample was moved to water for 24 h, a complete spectrum 
was obtained indicating significant helicity.  As mentioned previously, the high 
absorbance and noise problem was due to [PO43-] at pH 11.  Though special care was 
taken to reduce the amount of solvent carried over, it was likely that some amount of the 
1.0 M KPhos at pH 11.4 buffer remained in the water sample, raised the pH, and 
stabilized the peptide in a helical structure.  It is interesting that upon return to the 
original KPhos buffer, the sample did not return to its original intensity, but instead the 
48 (water) and 72 (buffer) hours samples were the same in the discernible region.  PolyQ 
under the same conditions (Figure 3-42) similarly did not regain its original structure.  

























Figure 3-51. Solvent exchange effect on encapsulated Aβ from H2O to 50.0 mM KPhos 




before the first spectrum was taken.  The same exchange protocol was utilized in treating 
the xerogel.  The sample was transferred to 50 mM KPhos at pH 11.4 for another 24 h, 
and the spectrum was retaken before returning it to water.  It can be seen that the sample 
did not return to its original spectrum at 72 h.  A similar situation was seen for polyQ 
(Figure 3-45) where the signal intensity decreased at 48 h, instead of increasing, and the 
72 h spectrum remained similar to the 48 h spectrum.  This may indicate that the 48 h 
structures were stabilized by the lower pH that was carried over upon return to the 
original solvent. 
 Results from Figures 3-46, 3-47, 3-48, and 3-51 are contradictory because the 
irreversibility in the spectra did not depend on the starting solvent.  All show a change 
between the 24 h and 48 h spectra, but from 48 h to 72 h the change was irreversible.  
What the figures do demonstrate is that when high pH was involved the spectra were not 
reversible.  
 
3.9. Unique Results of Other Investigations 
Several additional experiments were carried out to further characterize the 
peptides and the xerogel environment.  These included the use of different solvents for 
solvent exchange, exploration of a narrower range of HFIP concentrations to characterize 
Aβ’s transition out of the random coil spectra, use of different solvents to compare polyQ 






3.9.1. Influence of 80% Ethanol on PolyQ’s Secondary Structure 
The general influence of alcohols on protein secondary structure has been well 
characterized, and so the following experiment was carried out on polyQ.  The peptide 
was first incubated in 80% ethanol overnight, and the spectrum was taken, as shown in 
Figure 3-52 (blue).  The spectrum is similar to the helical conformation obtained in 
≥ 25% HFIP.  The sample was then moved to 10.0 mM KPhos at pH 6.9, at which time a 
separate second sample was prepared using fresh 10.0 mM KPhos at pH 6.9.  These 
solutions were allowed to equilibrate overnight before both spectra were taken.  The 
sample transferred from 80% ethanol (red) showed an increase at the 222 nm signal and a 
decrease at the signal near 207 nm, as compared to the sample exposed only to 10 mM 
KPhos.  This was most likely due to some ethanol being retained in the glass, inducing a 































Figure 3-52. Encapsulated polyQ shows an irreversible gain in helical structure upon 
solvent exchange from 80% ethanol to 10 mM KPhos, pH 6.9.  The arrow points from the 





3.9.2. Aβ’s Folding Transition 
The Aβ peptide demonstrated that it could take on different amounts of secondary 
structure when returned to the original HFIP concentration during solvent exchange, 
Figures 3-46 and 3-47.  To further investigate this transition, the following experiments 
were performed: a solvent exchange between water and 50:50 TFE in water and an 
exchange from higher to lower concentrations of HFIP using a new sample.  In the first 
exchange, TFE was chosen because of its helical inducing properties, similar to HFIP.  
Figure 3-53 gives the resulting spectra.  Following the same solvent exchange protocol 
given in Section 3.8, a glass sample was first equilibrated in water, moved to TFE, and 
then returned to water.  As expected, the peptide changed between the weak helical 
structure found in water, to an apparent beta conformation in TFE, and then returned to a 

























First 24 h in
water
24 h in 50:50
TFE:water
Second 24 h in
water
Figure 3-53. Encapsulated Aβ stored at 25°C for 24 h in H2O, then moved to 50% 
TFE/H2O for 24 h, and returned to H2O.  The spectra were taken at the end of the 24 h 
periods.  Both the structures in water are random-coil while in TFE solution they are beta.  
The same experiment has been repeated in shorter times, and in different alcohols 
(fluorinated and unfluorinated).  The loss of signal is most likely due to leaching of the 





the TFE spectrum could not be fully interpreted; the CD instrument crossed its suggested 
absorbance threshold at 208 nm.  The second spectrum in water was reduced in intensity 
but had the same spectral shape, indicating that leaching took place.  This leaching was 
more extensive than was seen in experiments with HFIP.  Because the fluorinated 
alcohols were not buffered, some of the inconsistency may be due to a difference in pH, 
and therefore charge of the peptide.  The shapes of the spectra suggest complete 
reversibility of the transition. 
 Figure 3-46 and 3-47 showed that all the Aβ samples in HFIP were able to return 
to an identical random coil conformation when in water. The second experiment was 
performed to investigate the transition between the random coil spectra and the enhanced 
spectra of the HFIP solutions to see if a stable intermediate was detectable.  This was 
done by taking samples that previously gave the apparent beta spectra in high HFIP 
concentrations and incubating them in 2.5%, 5%, and 7.5% HFIP solutions.  These 
samples were moved to water and then returned to their respective HFIP solutions.  After 
24 h in each solution at 25°C, the spectra were taken.  Initially, the HFIP exchanges were 
prepared in the following manner: 10%  2.5%, 35%  5%, and 50%  7.5%.  
Because each sample came from a different original HFIP concentration, the new starting 
concentrations (v/v) were estimated using the calculation from Section 3.8 for the sample 
in 5% HFIP.  For the other two combinations, the new initial and final concentrations 
would have been: 
2.5% initial = 100%((3.00 ml x 2.5%) + (0.04 ml x 10%))/3.04 ml = 2.60% 




7.5% initial = 100% ((3.00 ml x 7.5%) + (0.04 ml x 50%))/3.04 ml = 8.06% 
7.5% final = 100% (3.00 ml x 7.5%)/3.04 ml = 7.40%. 
The percent HFIP carried over to the water from the 8.06% sample works out to be 
0.01%, and so, in terms of significant figures, may be neglected. 
 Figure 3-54 shows the results for this experiment.  It can be seen that the 2.5% 
sample remained random coil throughout the experiment, the 5% sample gave an 
apparent beta signal when brought down from a higher concentration but was random 
when brought up from water, and the 7.5% sample yielded an apparent beta structure 
both times, though reduced when brought back up from water.   
 In solution, the beta structure of Aβ was apparently aggregation resistant (Figures 
3-25 and 3-30), but the results in Figure 3-54 indicate that it was sensitive to [HFIP].  In 
addition, it has been seen that, with increasing HFIP concentration, there was an increase 
in helical structure.  The existence of stable soluble oligomers has been well documented 
[11, 100, 101, 103], but monomeric beta structure is not.  In section 3.3.2.1, it was 
suggested that this spectrum could in fact represent beta structure (Figure 3-13 bottom 
panel inset).  Since it is believed that encapsulated Aβ is monomeric, it may be that the 
solution beta spectrum was that of stable soluble oligomers, whereas the encapsulated 
peptide was monomeric and contains significant helical structure in addition to beta 
structure. 
Figure 3-54 suggests that there was a very small thermodynamic barrier between 
the random coil conformation and the structure with enhanced ellipticity, Figure 3-55 for 








































































Figure 3-54. Encapsulated Aβ folding transition.  Encapsulated Aβ gives different 
spectra in the same solution, depending on its solution history.  All samples were stored 
in >10% HFIP solution for 24 h before being placed in 2.5% HFIP (top), 5% HFIP 








barrier is also the barrier to aggregation.  It was shown in Figure 3-13 (top) that the 5% 
HFIP sample was the lowest concentration to give any sign of secondary structure, and 








Figure 3-55. A representation of the two possible energetically close stable states for the 




3.9.3. Comparison of Encapsulated PolyQ and Aβ in Various Solvents 
Several well-characterized solvents were used in an attempt to find commonalities 
between the two peptides in this study and to possibly develop a unifying mechanism 
behind protein aggregation.  Because both peptides demonstrated a resistance to 
aggregation in KPhos at high pH, 50.0 mM KPhos pH 11.4 was included in the 
comparison (Figure 3-56).  A notable commonality is the general shape of the spectra that 
was likely due to the influence of the F3-propyl modifier.  All samples except those in 
80% ethanol were characterized by weak helical structure.  For polyQ, the 80% ethanol 
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Figure 3-56. Comparison of encapsulated polyQ and Aβ  in various solvents.  Top 
(polyQ) and bottom (Aβ).  Xerogel samples of polyQ show a loss of structure with an 
increase in pH, while Aβ shows the opposite.  The Aβ samples in 50.0 mM and 10.0 mM 
KPhos did not come from the same glass, so their spectra were adjusted to compensate 




to interpret.  As discussed in the previous section, this spectrum was most likely similar 
in shape to the other helical spectra in Figure 3-56.  They were similar in the fact that 
they both return intense signal strength.  Another notable difference is that polyQ samples 




can be explained by the relative charge distribution on each peptide.  PolyQ had its 
termini oppositely charged, so the monomeric peptide was soluble.  Aβ had positive and 
negative charges distributed intermittently along its backbone and also contained a 
hydrophobic region.  Uversky and Dunker (2010) [14] describe polar amino acids as 
residues that promote disorder within a polypeptide.  Therefore the peptide may have 
been adsorbed to the hydrophobic silica surface and/or may have remained largely 
unstructured.  This is seen by comparing the signal intensities to that of the samples in 
water.  The most notable difference is the intensities of the samples in 50.0 mM KPhos 
pH 11.4 samples.  PolyQ showed a weak helical structure at pH 11.4 that should not be 
due to adsorption since both it and the silica surface were negatively charged at this pH, 
but was more likely due to a lack of structure.  On the other hand, Aβ showed an 
enhanced helical structure at pH 11.  This may have been due to the fact that it was 
negatively charged like polyQ, keeping it from adsorbing to the silica surface, but Aβ 
also had a hydrophobic region, driving folding.  Most important was the similarity 
between the two most aggregation-prone structures, water and 10.0 mM KPhos at pH 6.9.  
These spectra return weak intensity and mainly random coil structures.  This indicated a 
lack of intermolecular hydrogen bonds for stabilizing secondary structure, verifying that 
the unfolded state is an aggregation prerequisite.  
 
3.9.4. Use of Buffer in Xerogel Preparation 
Because it took several days for both peptides to aggregate out of solution in 




matter of minutes, an attempt to create a sol-gel for each peptide was made with 
potassium acetate as a buffer at pH 4.6.  Unexpectedly, both glasses took 2 days to 
harden and contained visible “patches” of aggregated peptide.  The glass itself was clear, 
but it contained multiple 4-9 mm2 opaque regions.   Figure 3-57 gives the spectra of each 

























Figure 3-57. PolyQ and Aβ glass encapsulated peptides made with acetate buffer.  Both 







 The purpose of this work was to study two aggregate prone peptides, Aβ and 
polyQ, by encapsulating the peptides in a sol-gel matrix to prevent aggregation.  The first 
challenge was to solubilize the peptides so that they may be brought up in a solution and 
have the glass matrix form around them before aggregation occured.  As stated in Section 
3.1, two steps were identified as being most crucial to successful encapsulation of the 
monomer: (1) when solubilizing the peptide, the clarified solution must be allowed to sit 
overnight at room temperature (~14 h) in order to obtain consistent results, and (2) after 
the solubilized peptide had been dried, resuspension in TFA solution requires 
clarification by performing a series of repetitive pipettings over the course of ~1 h.  It 
then must have been allowed to rest for no less than an additional 30 min prior to use.  
Following these two peptide preparation steps gave consistent results in subsequent 
experiments. 
 For first attempts at encapsulation, leaching of the peptide was identified as a 
detrimental problem because, like aggregation, leaching cannot be controlled and leads to 
an unknown change in the peptide’s concentration making interpretation of the data 
difficult.  To minimize leaching, a protocol for making a xerogel was developed that still 
yielded optically transparent glasses for CD analysis.  In Section 3.2.2.1 it was shown 
that xerogels reduced leaching with an increase in signal due to a higher peptide 
concentration.  This was observed in Figures 3-1 to 3-4 where the only differences in the 
spectra were the intensities, not the general shape, and where leaching was studied as a 




in the wet-aged glasses, xerogel samples showed increased helicity or enhanced 
secondary structure compared to solution samples.  This was most likely due to the F3-
propyl modifier and to excluded volume effects as discussed in Section 3.3.1.1.   
It has been demonstrated that polyQ and Aβ peptides are stabilized against 
aggregation when immobilized in their monomeric form within a 10% trifluoropropyl 
silica glass xerogel.  The molecular confinement of the peptide prevented aggregation 
and minimized intermolecular interactions.  This idea is supported by results in Sections 
3.3.1.2 and 3.3.1.3 where Figures 3-8 to 3-11 suggest that the polyQ peptides were 
monomeric after encapsulation.  These results showed that soluble polyQ spectra directly 
overlap each other for different KPhos concentrations and pH values, pH 11 excluded.  
Under these same solvent conditions, the encapsulated peptide’s spectra separated out 
into distinct intensities that were dependent on both KPhos concentration and pH value.  
This is significant because the failure of the peptide to produce distinct solvent-dependent 
spectra in solution may suggest that polyQ forms intermolecular bonds, making the study 
of the monomeric form difficult by standard methods. 
Since the peptide was initially isolated in a monomeric form in the glass, there is 
also no question as to whether the spectra correspond to the monomeric or oligomeric 
forms.  In Section 3.3.2.1, it was demonstrated that Aβ transitioned from a random coil 
through an apparent beta structure to a mostly helical conformation (Figure 3-13).  These 
forms are seen often in the literature, but the sample usually contained soluble aggregates 
making it difficult to interpret.  Additionally, two of the papers discussed in Section 1.6 




[93] and for Aβ [101].  Here it was demonstrated that these red shifted beta-like signals 
most likely arose from a diffraction phenomenon and may be indicative of aggregating or 
aggregated peptides.  For examples see Figures 3-15 (diffraction spectrum), 3-16 (zero 
spectrum corresponding to 3-15), 3-31 (vortexed fibers), and 3-32 (aggregated polyQ in 
an under-prepared xerogel).   
This work agrees with most authors in that the peptides in this study aggregated 
most quickly in solution when near their isoelectric point.  Both peptides showed 
increased solubility at high pH where they contained a net negative charge.  These high 
pH samples have unresolved spectra because of high absorbance near 200 nm.  However 
it is clear that the peptides had an increase in ellipticity, supporting the hypothesis that 
increased secondary structure resists aggregation.  In addition, both peptides show 
increased solubility in time with increasing secondary structure (Figures 3-23 to 3-25 for 
polyQ, and 3-27 to 3-29 for Aβ).   
In solution, polyQ and Aβ showed a tendency to transition from a soluble helical 
structure to a beta structure, but under different peptide-specific conditions.  PolyQ had 
an isodichroic point, seen in Figure 3-20, which indicated a two-state transition between a 
random coil and beta structure in water.  Likewise, Aβ followed a similar transition in 
10% HFIP solution.  The difference is that polyQ showed a loss of signal indicating 
aggregation in water, whereas Aβ seemed to be stable in 10% HFIP (Figure 3-20 for 
polyQ, and Figures 3-26 and 3-30 for Aβ).  The stability of this beta fold was also 
demonstrated by Aβ’s resistance to thermal denaturization when encapsulated (Figure    




would it precipitate out?  In Section 3.7.2, it was shown that all thermal experiments in 
solution for both peptides were reversible, and, with the exception of minor leaching at 
high temperatures, so were the xerogel experiments. 
The majority of the solvent exchange experiments also demonstrated complete 
reversibility.  In Section 3.8, all exchanges with polyQ xerogels showed reversibility, and 
it was seen that low concentrations of HFIP actually reduced secondary structure (Figure 
3-41).  Encapsulated Aβ did not show reversibility in HFIP/water exchange experiments.  
Figure 3-47 shows that, upon return to the starting concentrations of 25%, 35%, and 50% 
HFIP, from water, all samples had the same spectral intensities.  This could be due to the 
formation of a stable intermediate or to irreversible adsorption to the glass.  Aβ also 
shows a folding intermediate over a narrow range of low HFIP concentrations.  
Encapsulated Aβ appeared to be able to take on two different structures at 5% HFIP, 
depending on whether the solvent conditions were approached from a higher HFIP 
concentration or from water (Figure 3-54).  In this case, the form with increased 
secondary structure also showed increased solubility in time.  Furthermore, both peptides 
showed the most random coil structure in the solutions in which they were most prone to 
aggregation (Figure 3-56).   
In summary, this work is in agreement with current theory on protein aggregation 
studies that implicate partially unstructured peptides as aggregation precursors.  
Furthermore, sol-gel encapsulated peptides separated into distinct solvent dependent 
spectra not seen in solution suggesting that the peptide was monomeric in the glass, 




studied under solvent conditions in which aggregation occurred for the soluble peptide, 
such as near the isoelectric point.  Therefore, this work demonstrates the ability to 
examine aggregation-prone peptides in solvent conditions that would be impossible by 





5. FUTURE WORK 
 Commonly, researchers use solvents that are well understood for their effects on 
proteins.  These solvents include salts and buffers (Hofmeister series), alcohols, crowding 
agents, etc.  In this study, KPhos buffers were used as a solvent variable, and, as a 
consequence, certain spectra could not be interpreted because of absorption and noise due 
to the high PO43- concentration at high pH.  It was also the high pH samples that proved 
to be aggregation resistant in time.  By the use of different salts and buffers, it may be 
beneficial to further investigate this structure since the results in Sections 3.3.1.3 and 
3.3.2.3 suggested that the enhanced ellipticity was most influenced by high pH.  In 
addition, since the high PO43- concentration should have also been a factor because it is a 
strong kosmotrope, careful consideration of the Hofmeister series may allow a 
comparable anion to be chosen, such as sulfate, which may not cause the same absorption 
and noise interference.  Furthermore, a more thorough investigation of the Hofmeister 
series is suggested to further characterize the peptide at all pH values.   
The F3-propyl modifier used in this study was likely to have increased the amount 
of helicity of the encapsulated peptide as compared to solution (Figure 3-6).  Successful 
encapsulation of the peptide in glasses using different metal alkaloid precursors may 
reveal important properties unique to disordered peptides, not only because of the 
influences of the silica surface on solvent properties, but also because the peptide remains 
soluble during network formation as the environment becomes more crowded.  Since it 
has been shown that the hydrophobicity of the precursor can influence the encapsulated 




structures to be seen in encapsulation, such as that seen in solution.  A range of 
precursors with different hydrophobicity should be tried, perhaps including a slightly less 
hydrophobic precursor such as propyltrimethoxysilane, the unfluorinated version of that 
used in this research. 
 The concentration of the F3-propyl modifier, or other precursors, could be varied 
to characterize the influences of the modifiers alone.  A new glass modifier may also 
allow for a lower modifier concentration to be used, better reproducing the solution 
behavior of the peptides in the encapsulated environment.  Such experiments would also 
determine whether leaching in the xerogel was reduced due to the F3-propyl modifier 
chemistry or due to a reduced channel size in the glass. 
A more thorough investigation of the encapsulation peptide’s stability in time and 
how its structure changes, or does not change, is suggested.  In this study, the solvent was 
not changed, so, in samples that were analyzed over long periods up to two months, there 
is the possibility that some HFIP evaporated.  A change in HFIP concentration could 
have influenced some of the results and may be overcome by regularly replenishing the 
solvent every couple of days.  During these long-term experiments, some encapsulated 
samples showed changes in secondary structure: namely Aβ’s transition to an apparent 
beta structure.  It would be interesting to see if, over a period of time greater than that 
used in this study, all samples transitioned to this beta structure.  And, can any changes 
be reversed by either solvent or temperature to a helical or random coil structure?  If 
irreversible changes are found, are they seen in solution?  If not, that may indicate an 




molecule to introduce that would stabilize the peptide and keep it from forming the 
irreversible state. 
 One such experiment would be a thermal experiment on soluble Aβ that has taken 
on the apparent beta structure in solution.  The current study only investigated the 
thermal folding and unfolding of helical and random coil structures that all showed 
complete reversibility, Section 3.7.  In solution, Aβ in 10% HFIP transitioned to an 
apparent beta structure.  Performing a thermal experiment on a sample showing this beta 
structure, at a very slow rate, may prove to be irreversible.  If the peptide aggregates out 
of solution, this would suggest that the thermally stable beta structure seen after 
encapsulation is on the aggregation pathway.  Should the soluble beta structure aggregate, 
then testing the transition to the beta fold may lead to the discovery of a small molecule 
that prevents its formation.  Studying this transition may be accomplished by standard 
solution methods, but in the glass, valuable information about aggregation-prone 
structures may be revealed by failed attempts because the peptide cannot aggregate.  A 
failed attempt would mean the peptide either transitions to the beta structure or the 
peptide aggregates out of solution.  In the glass, the peptide cannot aggregate out of 
solution so the structure can still be analyzed, and testing can be done to see if the 
structure is reversible.  Also, there is a strong possibility that multiple aggregation-prone 
states exist because there are multiple forms of aggregates.  Differentiating between these 
two scenarios is impossible by standard methods due to the simple fact that they 
aggregate out of solution.  After encapsulation, these different states may be identified, 




dependent characteristic may be identified, and a more in depth understanding of the 
aggregation-prone state may be developed. 
A second experiment would be to repeat the Aβ folding transition seen in Figure 
3-54 where the 5% HFIP sample showed two different structures depending on the prior 
solvent.  Closer investigation of this experiment, with more concentration values or slight 
variations in temperature, may reveal a destabilized state that is aggregation-prone.  
Repeating the experiment in solution by titration with HFIP or slight temperature 
variations would reveal whether the state is on the aggregation pathway.  If the peptide 
does aggregate, then the glass sample could be used to investigate different solutes for 
one that stabilizes the peptide against taking on the aggregation-prone state.  Again, it 
cannot be understated that these suggested experiments are only possible with the unique 
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